<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        361-212-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEVERA 30 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DACLATASVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2800
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AP07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>LEVERA contains the active ingredient daclatasvir. It is used to treat adults with hepatitis C, an infectious disease that affects the liver, caused by the hepatitis C virus.&nbsp;</p><p>&nbsp;</p><p>This medicine works by stopping the hepatitis C virus from multiplying and infecting new cells. This lowers the amount of hepatitis C virus in your body and removes the virus from your blood over a period of time.&nbsp;</p><p>&nbsp;</p><p>LEVERA must always be used together with other medicines against hepatitis C infection and must never be used by itself.&nbsp;</p><p>&nbsp;</p><p>It is very important that you also read the package leaflets for the other medicines that you will be taking with LEVERA. If you have any questions about your medicines, please ask your doctor or pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take LEVERA</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to daclatasvir or any of the other ingredients of this medicine (listed in section 6 of this leaflet).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking (by mouth or other ways that affect the whole body) any of the following medicines:</p><p>&minus; Phenytoin, carbamazepine, oxcarbazepine or phenobarbital, used to treat epileptic seizures.</p><p>&minus; Rifampicin, rifabutin or rifapentine, antibiotics used to treat tuberculosis.</p><p>&minus; Dexamethasone, a steroid used to treat allergic and inflammatory diseases.</p><p>&minus; Medicines containing St. John&rsquo;s wort (Hypericumperforatum, a herbal preparation).&nbsp;</p><p>&nbsp;</p><p>These medicines lower the effect of LEVERA and may result in your treatment not working. If you take any of these medicines, tell your doctor immediately.&nbsp;</p><p>&nbsp;</p><p>Since LEVERA must always be used in combination with other medicines against hepatitis C infection, please make sure that you read the &quot;Do not take&quot; section of the package leaflets for these medicines. If you are unsure of any information in the package leaflets, please contact your doctor or pharmacist.&nbsp;</p><p><strong>&nbsp;</strong></p><p>Warnings and precautions&nbsp;</p><p>Talk to your doctor or pharmacist before taking LEVERA.&nbsp;</p><p>&nbsp;</p><p>Tell your doctor if any of the following applies:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You currently take, or have taken in the last few months, the medicine amiodarone to treat irregular heartbeats (your doctor may consider alternative treatments if you have taken this medicine).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have an infection with the hepatitis B virus.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your liver is damaged and not functioning properly (decompensated liver disease).</p><p>&nbsp;</p><p>Tell your doctor immediately if you are taking any medicines for heart problems and during treatment you experience:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Light-headedness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting.</p><p>&nbsp;</p><p>Children and adolescents&nbsp;</p><p>LEVERA is not recommended for patients below 18 years of age. LEVERA has not yet been studied in children and adolescents.&nbsp;</p><p>&nbsp;</p><p>Other medicines and LEVERA</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because LEVERA may affect the way some medicines work. In addition some medicines may affect the way LEVERA works. Your doctor may need to adjust the dose of LEVERA or you may not be able to take LEVERA with certain medicines.&nbsp;</p><p>&nbsp;</p><p>Do not take LEVERA if you are taking any of the following medicines:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenytoin, carbamazepine, oxcarbazepine or phenobarbital, used to treat epileptic seizures.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin, rifabutin or rifapentine, antibiotics used to treat tuberculosis.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dexamethasone, a steroid used to treat allergic and inflammatory diseases.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines containing St. John&rsquo;s wort (Hypericumperforatum, a herbal preparation).&nbsp; These medicines lower the effect of LEVERA so your treatment will not work. If you take any of these medicines, tell your doctor immediately.&nbsp;</p><p>&nbsp;</p><p>Tell your doctor if you take any of the following medicines:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amiodarone or digoxin, used to treat irregular heartbeats.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atazanavir/ritonavir, atazanavir/cobicistat,elvitegravir/cobicistat/emtricitabine/tenofovirdisoproxilfumarat e combination tablet, etravirine, nevirapine or efavirenz, used to treat HIV infection.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Boceprevir or telaprevir, used to treat hepatitis C infection.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clarithromycin, telithromycin or erythromycin, used to treat bacterial infections&nbsp; &bull; Dabigatranetexilate, used to to prevent blood clots.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ketoconazole, itraconazole, posaconazole or voriconazole, used to treat fungal infections.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Verapamil, diltiazem, nifedipine or amlodipine, used to decrease blood pressure&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rosuvastatin, atorvastatin, fluvastatin, simvastatin, pitavastatin or pravastatin, used to lower blood cholesterol.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral contraceptives.</p><p>With some of these medicines, your doctor may need to adjust your dose of LEVERA.</p><p>&nbsp;</p><p>Pregnancy and contraception&nbsp;</p><p>Tell your doctor if you are pregnant, think you may be pregnant or are planning to become pregnant. If you become pregnant, stop taking LEVERA and tell your doctor immediately.&nbsp;</p><p>&nbsp;</p><p>If you are pregnant you must not take LEVERA.&nbsp;</p><p>If you can become pregnant, use effective contraception during and for 5 weeks after your treatment with LEVERA.&nbsp;</p><p>&nbsp;</p><p>LEVERA is sometimes used together with ribavirin. Ribavirin can harm your unborn baby. It is therefore very important that you (or your partner) do not become pregnant during this treatment.&nbsp;</p><p><strong>&nbsp;</strong></p><p>Breast-feeding&nbsp;</p><p>It is not known whether LEVERA passes into human breast milk. You should not breastfeed during treatment with LEVERA.&nbsp;</p><p><strong>&nbsp;</strong></p><p>Driving and using machines&nbsp;</p><p>Some patients have reported dizziness, difficulty concentrating, and vision problems while taking LEVERA with other medicines for their hepatitis C infection. If you have any of these side effects, do not drive or use any tools or machines.&nbsp;</p><p><strong>&nbsp;</strong></p><p>LEVERA contains lactose&nbsp;</p><p>If you have been told by your doctor that you have an intolerance to some sugars (e.g.</p><p>lactose), talk to your doctor before taking LEVERA.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. <strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Recommended dose&nbsp;</p><p>The recommended dose of LEVERA is <strong>60 mg once a day</strong>. Swallow the tablet whole. Do not chew or crush the tablet as it has a very unpleasant taste. LEVERA can be taken with or without a meal. <strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Some other medicines can interact with LEVERA, affecting the levels of LEVERA in your body. If you are taking any of these medicines, your doctor may decide to change your daily dose of LEVERA to ensure that the treatment is safe and effective for you. <strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Since LEVERA must always be used with other medicines against hepatitis C infection, please read the package leaflets for these medicines. If you have any questions, ask your doctor or pharmacist. <strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>How long to take LEVERA</p><p>Make sure you take LEVERA for as long as your doctor has told you to take it. <strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>The duration of your treatment with LEVERA will be either 12 or 24 weeks. The duration of your treatment will depend on whether you have previously received treatment for your hepatitis C infection, the condition of your liver, and what other medicines you will take with LEVERA. You may have to take your other medicines for different lengths of time. <strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>If you take more LEVERA than you should&nbsp;</p><p>If you accidentally take more LEVERA tablets than your doctor recommended, contact your doctor at once or contact the nearest hospital for advice. Keep the tablet blister with you so that you can easily describe what you have taken. <strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>If you forget to take LEVERA</p><p>It is important not to miss a dose of this medicine.&nbsp;</p><p>If you do miss a dose:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and you notice within 20 hours of the time you usually take LEVERA, you must take the tablet as soon as possible. Then take the next dose at your usual time.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and you notice 20 hours or more after the time you usually take LEVERA, wait and take the next dose at your usual time. Do not take a double dose (two doses close together). <strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>If you stop taking LEVERA</p><p>It is important that you continue to take LEVERA during the whole treatment period. Otherwise the medicine may not work against the hepatitis C virus. <strong>Do not stop taking LEVERA unless your doctor told you to stop.&nbsp; </strong></p><p><strong>&nbsp;</strong></p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.&nbsp;</p><p>&nbsp;</p><p>When LEVERA is used together with sofosbuvir (without ribavirin), the following side effects have been reported.&nbsp;</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10 people):&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, fatigue.</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people):<strong> </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty sleeping.<strong> </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Migraine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea (feeling sick), diarrhoea, abdominal pain.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain, aching or tender muscles, not caused by exercise.</p><p>&nbsp;</p><p>When LEVERA is used together with sofosbuvir and ribavirin, the following side effects have been reported.&nbsp;</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10 people):<strong> </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, nausea (feeling sick), fatigue.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in red blood cells (anaemia).</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people):<strong> </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty sleeping, irritability.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Migraine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath, cough, nasal congestion (blocked nose).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hot flush.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry skin, unusual hair loss or thinning, rash, itching.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, vomiting, abdominal pain, constipation, heartburn, excessive gas in the stomach or bowel.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain, aching or tender muscles, not caused by exercise.</p><p>&nbsp;</p><p>When LEVERA is used together with peginterferonalfa and ribavirin the reported side effects are the same as those listed in the package leaflets for these medicines. The most common of these side effects are listed below.&nbsp;</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10 people):<strong> </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty sleeping.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu-like illness, fever.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching, dry skin, unusual hair loss or thinning, rash.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain, aching or tender muscles, not caused by exercise, unusual weakness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritability.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in red blood cells (anaemia), reduction in white blood cells.</p><p>&nbsp;</p><p>Reporting of side effects&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and blister after &quot;EXP&quot;. The expiry date refers to the last day of that month.&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine does not require any special storage conditions.&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What LEVERA contains&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is daclatasvir. Each film-coated tablet contains 30 mg daclatasvir (as dihydrochloride)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&minus; Avicel pH 112, Lactose Anhydrous NF D.C., Croscarmellose Sodium Type A, Magnesium Stearate, Colloidal Silicon Dioxide, Opadry 03B110007 Green and Purified Water BP.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                LEVERA 30 mg:A light green to green coloured, round, biconvex film-coated tablet, engraved with “75” on one sideand plain on the other side. 
LEVERA 30 mg film-coated tablets are available in packs of 28 tablets in Reel OPA/AL/PVC with Aluminum Foil. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO</p><p>Al-Qassim Pharmaceutical Plant</p><p>Saudi Pharmaceutical Industries &amp; Medical Appliances Corporation.</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>المادة الفعالة التي يحتوي عليھا ليڤيرا ھي داكلاتاسڤير.&nbsp; يسُتخدم ھذا الدواء لعلاج البالغين الذين يعانون من التھاب الكبد الوبائي سي،&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وھو مرض معدِي صيب الكبد ،ينتج عن فيروس التھاب الكبد الوبائي سي .</p><p>&nbsp;</p><p>ويعمل ھذا الدواء عنطر يقوقف فيروس الإلتھاب الكبدي سي من التكاثر و إصابة خلايا جديدة. وھذا يقُلل من كمية الإلتھاب الكبدي الوبائي سي في الجسم، و يزُيل الفيروس من الدم على مدى فترة من الزمن.</p><p>&nbsp;</p><p>يجب أن تستخدم ليڤيرا دائما جنبا إلى جنب مع غيرھا من الأدوية ضد عدوى الإلتھاب الكبدي الوبائي سي، ويجب ألا يسُتخدم بمفرده &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;نھائياً.</p><p>&nbsp;</p><p>من الھام جدا أًنتقوم بقراءة النشرات الداخلية الخاصة بالأدوية الأخرى التي سوف تتناولھا مع ليڤيرا أيضا ً.</p><p>إذا كانت لديك أي أسئلة حول الأدوية الخاصة بك، فضلاً استشر طبيبك أو الصيدلي.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول ليڤيرا&nbsp; </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية من داكلاتاسڤير أو أي من المكونات الأخرى من ھذا الدواء (المدرجة في الفقرة 6 من ھذه النشرة).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول (عن طريق الفم أوعن طريق أي وسائل أخري قد تؤثر على الجسم كله) أي من الأدوية التالية:&nbsp;</p><p>&minus; فينيتوين، كاربامازيبين، اوكسكاربازيبين أو الفينوباربيتال، والتي تستخدم لعلاج نوبات الصرع.</p><p>&minus; ريفامبيسين، ريفابيوتين أو ريفابينتين، والمضادات الحيوية المستخدمة لعلاج السل.</p><p>&minus; ديكساميثازون، الستيرويد المستخدم لعلاج أمراض الحساسية و الإلتھابات.</p><p>&minus; الأدوية التي تحتوي على نبتة القديس جونز (ھايبريكم بيرفوراتوم، مستحضر عشبي).</p><p>&nbsp;</p><p>&nbsp;ھذھ الأدوية تقُلل من تأثير ليڤير او يمكن أن تؤدي إلي وقف فعالية العلاج. إذاكنت تتناول أي من ھذھ الأدوية، أخبر طبيبك فورا.&nbsp;</p><p>&nbsp;</p><p>لأن ليڤيرا يجب دائما أن يسُتخدم بجانب أدوية أخرى ضد الإلتھاب الكبدي الوبائي سي، يرُجى التأكد من أنك قد قمت بقراءة فقرة &quot;لا تتناول&quot; من النشرات الداخلية لھذھ الأدوية.&nbsp; إذا لم تكن متأكدا مًن أي معلومات في النشرات الداخلية، فضلاً قم بالتواصل مع طبيبك أو الصيدلي.&nbsp;</p><p>&nbsp;</p><p><strong>التحذيرات والاحتياطات </strong></p><p>فضلاً قم بالتحدث مع طبيبك أو الصيدلي قبل تناول ليڤيرا.</p><p>&nbsp;</p><p>أخبر طبيبك إذا كان أي مما يلي ينطبق عليك:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول حاليا، أو قد تناولت في الأشھر القليلة الماضية، دواء الأميودارون المستخدم في علاج عدم انتظام ضربات القلب (قد يلجأ طبيبك إلي أدوية بديلة إذا كنت تناولت ھذا الدواء).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك عدوى بفيروس الإلتھاب الكبدي الوبائي ب.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تليف بالكبد و لا يقوم بوظائفه الحيوية بشكل مناسب (المرض الكبدي اللا تعويضي) .</p><p>&nbsp;</p><p>أخبر طبيبك فورا إذا كنت تتناول أي أدوية لعلاج أمراض القلب وخلال فترة العلاج واجھت:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء.</p><p>&nbsp;</p><p><strong>الأطفال و المراھقين </strong></p><p>لا ينُصح بتناول ليڤيرا للمرضى الأقل من 18 سنة من العمر. لم يتم بعد دراسة تناول ليڤيرا في الأطفال و المراھقين.&nbsp;</p><p>&nbsp;</p><p><strong>تناول الأدوية الأخري وليڤيرا&nbsp; </strong></p><p>أخبر طبيبك أو الصيدلي إذاكنت تتناول، أو قد تناولت مؤخرا أًوقد تتناول أي أدوية أخرى. وذلك لأن ليڤيرا قد يؤثرعلى فعالية بعض الأدوية.</p><p>وبالإضافة إلى ذلك قد تؤثر بعض الأدوية علي فعالية ليڤيرا. قد يلجأ طبيبك إلى تعديل جرعة ليڤيرا أومن الممكن ألا تكون&nbsp; قادراًعلى تناول ليڤيرا مع بعض الأدوية.&nbsp;</p><p>لا تقم بتناول ليڤيرا إذا كنت تتناول أياً من الأدوية التالية:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين، كاربامازيبين، اوكسكاربازيبين أو الفينوباربيتال، والتي تستخدم لعلاج نوبات الصرع.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين، ريفابيوتين أو ريفابينتين، والمضادات الحيوية المستخدمة لعلاج السل.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديكساميثازون، الستيرويد المستخدم لعلاج أمراض الحساسية و الإلتھابات.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تحتوي على نبتة القديس جونز (ھايبريكم بيرفوراتوم، مستحضر عشبي).</p><p>&nbsp;ھذھ الأدوية تقُلل من تأثي رليڤيرا و يمكن أن تؤدي إلي وقف فعالية العلاج. إذا كنت تتناول أي من ھذھ الأدوية،&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك فوراً.&nbsp;</p><p>&nbsp;</p><p>أخبر طبيبك إذا كنت تتناول أياً من الأدوية التالية:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اميودارون أو ديجوكسين، والتي تستخدم لعلاج عدم انتظام ضربات القلب.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتازاناڤير/ ريتوناڤير، اتازاناڤير/ كوبيسيتات، الدواء الذي يحتوي علي إلڤيتيجراڤير/ كوبيسيتات/ إيمتريسيتابين/ تينوفوڤير ديسوبروكسيل فيومارات في قرص واحد، إيتراڤيرين، نيفيرابين أو ايفاڤيرينز، والتي تستخدم لعلاج فيروس نقص المناعة البشرية.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوسيبريڤير أو تيلابريڤير، والتي تستخدم لعلاج العدوى بفيروس الالتھاب الكبدي سي .</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلاريثروميسين، تيليثروميسين أوالإريثروميسين، والتي تستخدم لعلاج الالتھابات البكتيرية.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دابيجاتران إيتيكسيلات، والذي&nbsp; يسُتخدم لمنع تجلط الدم. &nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول، إيتراكونازول، بوساكونازول أو ڤوريكونازول، والتي&nbsp; تسُتخدم لعلاج الالتھابات الفطرية .</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ڤيراباميل، ديلتيازيم، نيفيديبين أو أملوديبين، والتي&nbsp; تسُتخدم لخفض ضغط الدم.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; روسيوڤاستاتين،أتورفاستاتين،فلوڤاستاتين،سيمڤاستاتين،بيتاڤاستاتينأوبراڤاستاتين،والتي&nbsp; تسُتخدم لخفض نسبة الكولستيرول في الدم.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وسائل منع الحمل التي يتم تناولھا عن طريق الفم.</p><p>مع بعض من ھذھ الأدوية، قد يحتاج طبيبك إلي تعديل الجرعة التي تتناولھا منليڤيرا.&nbsp;</p><p>&nbsp;</p><p><strong>الحمل ووسائل منع الحمل </strong></p><p>أخبري طبيبك إذا كنتِ حاملا ً،أو تعتقدين أنك قد تكوني حاملا أو تخططين لتصبحي حاملا ً.&nbsp; إذا أصبحتِ حملا ً،توقفي عن تناول ليڤيرا وأخبري طبيبك فورا ً.</p><p>&nbsp;</p><p>&nbsp;إذا كنت حاملًا يجب ألا تقومي بتناول ليڤيرا.</p><p>إذا كان من الممكن أن تصبحي حاملا ً،قومي باستخدام وسيلة فعالة لمنع الحمل أثناء ولمدة 5 أسابيع بعد العلاج بليڤيرا.</p><p>&nbsp;</p><p>يستخدم ليڤيرا أحيانا جنبا إلى جنب مع ريبافيرين. من الممكن أن يضر ريبافيرين طفلك الذي لم يولد بعد. ولذا فمن المھم جدا ألا تصبحي حاملا ً (أو شريك حياتك) أثناء ھذا العلاج.&nbsp;</p><p>&nbsp;</p><p><strong>الرضاعة الطبيعية </strong></p><p>من غير المعروف ما إذا كان ليڤيرا يصل إلي حليب الثدي البشري. يجب عليكي ألا تقومي بالرضاعة الطبيعية خلال فترة العلاج باستخدام ليڤيرا.</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong>&nbsp;</p><p>أبلغ بعض المرضى عن دوخة، صعوبة في التركيز، ومشاكل في الرؤية أثناء تناول ليڤيرا مع أدوية أخرى لعلاج</p><p>عدوى التھاب الكبد الوبائي سي المصابين به. إذا كانت لديك أي من ھذھ الآثار الجانبية، لا تقم بالقيادة أواستخدام أي أدوات أو آلات.</p><p>&nbsp;</p><p><strong>يحتوي ليڤيرا على اللاكتوز </strong></p><p>إذا أخبرك طبيبك أن لديك عدم قدرة علي تحمل بعض السكريات (مثل اللاكتوز)،استشر طبيبك قبل تناول ليڤيرا.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائما ً بتناول ھذا الدواء كما أخبرك طبيبك.استشر طبيبك أو الصيدلي إذا لم تكن متأكدا ً.</p><p>&nbsp;</p><p><strong>الجرعة الموصى بھا </strong></p><p>الجرعة الموصى بھا منليڤيرا ھي 60 ملجم مرة واحدة يوميا ً. قم ببلع القرص بأكمله. لا تقم بمضغ أوسحق القرص</p><p>&nbsp;</p><p>لما له من طعم غير طيب للغاية. يمكن تناول ليڤيرا معأ وبدون الوجبات.&nbsp;</p><p>&nbsp;</p><p>يمكن لبعض الأدوية الأخرى أن تتفاعل مع ليڤيرا، مما يؤثرعلى مستويات ليڤيرا فيجسمك. إذاكنت تتناول أياً من ھذھ الأدوية، فقد يقرر طبيبك تغيير الجرعة اليومية من ليڤيرا للتأكد من سلامة وفعالية العلاج بالنسبة لك.</p><p>&nbsp;</p><p>لأن ليڤيرا يجب دائما أًن يسُتخدم بجانب أدوية أخرى ضد الإلتھاب الكبدي الوبائي سي، فضلا ً قم بقراءة النشرات الداخلية لھذھ الأدوية. إذا كانت لديك أي أسئلة، استشر طبيبك أو الصيدلي.&nbsp;</p><p><strong>&nbsp; </strong></p><p><strong>فترة تناول ليڤيرا </strong></p><p>تأكد من أنك تتناول ليڤيرا طوال الفترة التي أخبرك بھا طبيبك.</p><p>&nbsp;</p><p>فترة العلاج بليڤيرا تكون لمدة 12 أو 24 أسبوعا ً. تعتمد مدة العلاج على ما إذا كنت قد تلقيت سابقا علاج لعدوى التھاب الكبد الوبائي سي، وحالة الكبد، و ماھي الأدوية الأخرى التي سوف تتناولھا مع ليڤيرا.</p><p>قد تضطر إلى تناول الأدوية الأخرى الخاصة بك لفترات مختلفة من الزمن.&nbsp;</p><p>&nbsp;</p><p><strong>إذا تناولت ليڤيرا أكثر مما ينبغي&nbsp; </strong></p><p>إذا تناولت جرعة زائدة من أقراص ليڤيرا عن الجرعة الموصي بھا من قبِل طبيبك عن غير قصد، قم بالتواصل مع طبيبك على الفور أو قم بالتواصل مع أقرب مستشفى للحصول على الاستشارة. قم بالحفاظ على الشريط الخاص بالأقراص معك بحيث يمكنك بسھولة وصف الدواء الذي تناولته.</p><p>&nbsp;</p><p><strong>إذا نسيت تناول ليڤيرا </strong></p><p>من المھم عدم نسيان تناول أي جرعة من ھذا الدواء.</p><p>إذا نسيت تناول جرعة من الدواء:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ولاحظت ذلك فيغضون 20 ساعة من ميعادك المعتاد لتناول ليڤيرا، قم بتناول القرص في أقرب وقت ممكن. ثمقم بتناول الجرعة التالية في الوقت المعتاد.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ولاحظت ذلك بعد 20 ساعة أو أكثر من ميعادك المعتاد لتناول ليڤيرا، انتظر وتناول</p><p>الجرعة التالية في الوقت المعتاد. لا تقم بتناول جرعة مضاعفة (جرعتين في وقت قريب من بعضھما البعض).</p><p>&nbsp;</p><p><strong>إذا توقفت عن تناول ليڤيرا&nbsp; </strong></p><p>من المھم أن تستمر في تناول ليڤيرا خلال فترة العلاج كاملة. وإلا فقد لا يعمل الدواء بشكل فعال ضد فيروس التھاب الكبد الوبائي سي.</p><p><strong>لا تتوقف عن تناول ليڤيرا إلا إذا أخبرك طبيبك بأن تتوقف.</strong></p><p>&nbsp;</p><p>إذا كانت لديك أي أسئلة أخرى عن استخدام ھذا الدواء، إسأل طبيبك أو الصيدلي.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لھذا الدواء أن يسبب أعراض جانبية، على الرغم من أنه ليس كل شخص يتعرض لھا.&nbsp;</p><p>&nbsp;</p><p>عند استخدام ليڤيرا &nbsp;جنباً إلى جنب مع سوفوسبوڤير( بدونريباڤيرين)، قد تم الإبلاغ عن الآثار الجانبية التالية.&nbsp;</p><p>&nbsp;</p><p><strong>شائعة &nbsp; &nbsp;جداً</strong>(قد تؤثر على أكثر من 1 في كل 10 أشخاص):&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع، والتعب.</p><p>&nbsp;</p><p><strong>شائعة</strong> ( قد تؤثر على ما يصل إلى 1 في كل 10 أشخاص):&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع نصفي.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان (شعور بالإعياء)،و الإسھال، و آلام في البطن.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل، آلام أو لين العضلات، الغير ناجمة عن ممارسة الرياضة.</p><p>&nbsp;</p><p>عند استخدام ليڤيرا جنبا إًلى جنب مع سوفوسبوفير و ريبافيرين، تم الإبلاغ عن الآثار الجانبية التالية.&nbsp;</p><p>&nbsp;</p><p><strong>شائعة &nbsp; &nbsp;جداً</strong>(قد تؤثر على أكثر من 1 في كل 10 أشخاص):&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، غثيان (شعور بالإعياء)،والتعب.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في خلايا الدم الحمراء (فقر الدم).&nbsp;</p><p>&nbsp;</p><p><strong>شائعة</strong> ( قد تؤثر على ما يصل إلى 1 في كل 10 أشخاص):&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الشھية.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم، والتھيج المفرط.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع نصفي.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس، والسعال، احتقان الأنف (انسداد الأنف).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توھج ساخن.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الجلد، فقدان الشعر أو نقص كثافته بشكل غير اعتيادي، والطفح الجلدي، والحكة.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسھال، والقيء، وآلام البطن، والإمساك، وحرقة المعدة، والغازات الزائدة في المعدة أو الأمعاء.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل، آلام أو لين العضلات، الغير ناجمة عن ممارسة الرياضة.</p><p>&nbsp;</p><p>الآثار الجانبية المبلغ عنھا عند استخدام ليڤيرا &nbsp; &nbsp;جنبا إًلى جنب مع ألفابيج انترفيرون و ريباڤيرين ھي نفس تلك الآثار المذكورة في النشرات الداخلية لھذھ الأدوية. الآثار الجانبية الأكثر شيوعا منھا مذكورة أدناه.&nbsp;</p><p><strong>شائعة &nbsp; &nbsp;جداً</strong>(قد تؤثر على أكثر من 1 في كل 10 أشخاص):&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الشھية.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة فيالنوم.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الرأس.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مرضية تشبه أعراض الإنفلونزا، والحمى.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة، جفاف الجلد، فقدان الشعر أو نقص كثافته بشكل غير اعتيادي، والطفح الجلدي.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسھال.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل، آلام أو لين العضلات، الغير ناجمة عن ممارسة الرياضة، ضعف غير معتاد.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھيج المفرط.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في خلايا الدم الحمراء (فقر الدم)،انخفاض في خلايا الدم البيضاء.</p><p>&nbsp;</p><p><strong>الإبلاغ عن الآثار الجانبية </strong></p><p>اذا ظھرت عليك أي آثار جانبية، قم بالتحدث مع طبيبك أو الصيدلي. &nbsp;ويشمل ذلك أي آثار جانبية محتملة غير المُدرجة في ھذھ النشرة.</p><p>يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة. يمكنك من خلال الإبلاغ عنالآثارالجانبيةأنتساعدفيتوفيرالمزيدمنالمعلوماتحولسلامةھذاالدواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحُفظ ھذا الدواء &nbsp; &nbsp;بعيداً عن متناول ونظر الأطفال.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحُفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل ھذا الدواء بعد انتھاء تاريخ الصلاحية المدون على العبوة بعد EXP. وتاريخ الإنتھاء يشير إلى أخر يوم فى الشھر المذكور.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يتطلب ھذا الدواء أي ظروف تخزين خاصة.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية في مياه المجاري أو قمامة المنزل. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجتھا. لأن ھذه الاعتبارات ستعمل على حماية البيئة.&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة ھي داكلاتاسڤير. كل قرص مغلف بطبقة رقيقة يحتوي علي 30 ملجم&nbsp; داكلاتاسڤير (علي ھيئة ثنائي الھيدروكلورايد).&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخري ھي:&nbsp;</p><p>&minus; أڤيسل بمعدل حموضة 112، لاكتوز لامائي إن إف دي.سي.، صوديوم كروسكارميللوز من الفئة أ ،ستيارات الماغنسيوم، ثنائي السيليكون الغروي، أوبادري 110007بي03 أخضر، وماء مقطر بي بي.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ليڤيرا 30 ملجم: قرص مغلف بطبقة رقيقة، لونھ أخضر فاتح إلى أخضر اللون، دائري، محد بالوجھين، منقوش علي أحد الجانبين &quot;75&quot; و خالي من العلامات على الجانب الأخر. ليڤيرا 30 ملجم أقراص مغلفة بطبقة رقيقة متاحة في عبوات من 28 قرص في شرائط من أو بي إيه/إيه إل/بي ڤي سي مع رقائق الألومنيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مصنع الأدوية بالقصيم</p><p>الشركة السعودية للصناعات الدوائية والمستلزمات الطبية المملكة العربية السعودية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر 2017 .                      
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LEVERA 30 mg film-coatedtablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LEVERA 30 mg film-coated tablets
Each film-coated tablet contains 33 mg daclatasvir dihydrochloride equivalent to 30 mg daclatasvir.
Excipient(s) with known effect
Each 30mg film-coated tablet contains 85.250 mg of lactose (as anhydrous).
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

LEVERA 30 mg film-coated tablets
A light green to green coloured, round, biconvex film-coated tablet, engraved with “75” on one sideand plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LEVERA is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV)infection in adults (see sections 4.2, 4.4 and 5.1).</p><p>&nbsp;</p><p>For HCV genotype specific activity, see sections 4.4 and 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with LEVERA should be initiated and monitored by a physician experienced in the management of chronichepatitis C.</p><p>&nbsp;</p><p><u>Posology</u></p><p>The recommended dose of LEVERA is 60 mg once daily, to be taken orally with orwithout meals.</p><p>&nbsp;</p><p>LEVERA must be administered in combination with other medicinal products. The Summary of Product Characteristicsfor the other medicinal products in the regimen should also be consulted before initiation of therapy with LEVERA.</p><p>&nbsp;</p><p><strong>Table 1: Recommended treatment for LEVERA interferon-freecombination therapy</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Patient population*</strong></p></td><td style="vertical-align:top"><p><strong>Regimen and duration</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>HCV GT 1 or 4</em></p></td></tr><tr><td style="vertical-align:top"><p>Patients without cirrhosis</p></td><td style="vertical-align:top"><p>LEVERA + sofosbuvir for 12 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Patients with cirrhosis</p><p><em>&nbsp;</em></p><p><em>CP A or B</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>CP C</em></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>LEVERA + sofosbuvir + ribavirin for 12 weeks</p><p>or</p><p>LEVERA + sofosbuvir (without ribavirin) for 24 weeks</p><p>&nbsp;</p><p>LEVERA + sofosbuvir +/- ribavirin for 24 weeks</p><p>(see sections 4.4 and 5.1)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>HCV GT 3</em></p></td></tr><tr><td style="vertical-align:top"><p>Patients without cirrhosis</p></td><td style="vertical-align:top"><p>LEVERA + sofosbuvir for 12 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Patients with cirrhosis</p></td><td style="vertical-align:top"><p>LEVERA + sofosbuvir +/- ribavirin for 24 weeks</p><p>(see section 5.1)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Recurrent HCV infection post-liver transplant (GT 1, 3 or 4)</em></p></td></tr><tr><td style="vertical-align:top"><p>Patients without cirrhosis</p></td><td style="vertical-align:top"><p>LEVERA + sofosbuvir + ribavirin for 12 weeks</p><p>(see section 5.1)</p></td></tr><tr><td style="vertical-align:top"><p>Patients with CP A or B cirrhosis</p><p>GT 1 or 4</p><p>&nbsp;</p><p>GT 3</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>LEVERA + sofosbuvir + ribavirin for 12 weeks</p><p>&nbsp;</p><p>LEVERA + sofosbuvir +/- ribavirin for 24 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Patients with CP C cirrhosis</p></td><td style="vertical-align:top"><p>LEVERA + sofosbuvir +/- ribavirin for 24 weeks</p><p>(see sections 4.4 and 5.1)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>GT: Genotype; CP: Child Pugh</p><p>* Includes patients co-infectedwith human immunodeficiency virus (HIV). For dosing recommendations with HIVantiviral agents, refer to section 4.5.</p><p>&nbsp;</p><p><em><u>LEVERA + peginterferon alfa + ribavirin</u></em></p><p>This regimen is an alternative recommended regimen for patients with genotype 4 infection, without cirrhosis or withcompensated cirrhosis. LEVERA is given for 24 weeks, in combination with 24-48 weeks of peginterferon alfa andribavirin:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If HCV RNA is undetectable at both treatment weeks 4 and 12, all 3 components of the regimen should be continuedfor a total duration of 24 weeks.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If undetectable HCV RNA is achieved, but not at both treatment weeks 4 and 12, LEVERA should be discontinued at24 weeks and peginterferon alfa and ribavirin continued for a total duration of 48 weeks.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Ribavirin Dosing Guidelines</em></p><p><em>&nbsp;</em></p><p>The dose of ribavirin, when combined with LEVERA, is weight-based(1,000 or 1,200 mg in patients &lt;75 kg or &ge;75 kg,respectively). Refer to the Summary of ProductCharacteristics of ribavirin.</p><p>&nbsp;</p><p>For patients with Child-Pugh A, B, or C cirrhosis or recurrence of HCV infection after liver transplantation, therecommended initial dose of ribavirin is 600 mg daily with food.If the starting dose is well-tolerated,the dose can betitrated up to a maximum of1,000-1,200mg daily (breakpoint 75 kg). If the starting dose is not well-tolerated,the dose</p><p>should be reduced as clinically indicated, based on haemoglobin and creatinine clearance measurements (see Table 2).</p><p>&nbsp;</p><p><strong>Table 2: Ribavirin dosing guidelines for co-administration with LEVERA regimen for patients with cirrhosis or post-transplant</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Laboratory Value/Clinical Criteria</strong></p></td><td style="vertical-align:top"><p><strong>Ribavirin Dosing Guideline</strong></p></td></tr><tr><td style="vertical-align:top"><p>Haemoglobin</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt;12 g/dL</p></td><td style="vertical-align:top"><p>600 mg daily</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 10 to &le;12 g/dL</p></td><td style="vertical-align:top"><p>400 mg daily</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 8.5 to &le;10 g/dL</p></td><td style="vertical-align:top"><p>200 mg daily</p></td></tr><tr><td style="vertical-align:top"><p>&le;8.5 g/dL</p></td><td style="vertical-align:top"><p>Discontinue ribavirin</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine Clearance</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt;50 mL/min</p></td><td style="vertical-align:top"><p>Follow guidelines above for haemoglobin</p></td></tr><tr><td style="vertical-align:top"><p>&gt;30 to &le;50 mL/min</p></td><td style="vertical-align:top"><p>200 mg every other day</p></td></tr><tr><td style="vertical-align:top"><p>&le;30 mL/min or haemodialysis</p></td><td style="vertical-align:top"><p>Discontinue ribavirin</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><em>Dose modification, interruption and discontinuation</em></p><p><em>&nbsp;</em></p><p>Dose modification of LEVERA to manage adverse reactions is not recommended. If treatment interruption of components in the regimen is necessary because of adverse reactions, LEVERA must not be given as monotherapy.</p><p>&nbsp;</p><p>There are no virologic treatment stopping rules that apply to the combination of LEVERA with sofosbuvir.</p><p>&nbsp;</p><p><em>Treatment discontinuation in patients with inadequate on-treatment virologic response during treatment with LEVERA,peginterferon alfa and ribavirin</em></p><p><em>&nbsp;</em></p><p>It is unlikely that patients with inadequate on-treatment virologic response will achieve a sustained virologic response(SVR); therefore discontinuation of treatment isrecommended in these patients. The HCV RNA thresholds that trigger discontinuation of treatment (i.e. treatment stopping rules) are presented in Table 3.</p><p>&nbsp;</p><p><strong>Table 3: Treatment stopping rules in patients receiving LEVERA in combination with peginterferon alfa andribavirin with inadequate on-treatment virologic response</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>HCV RNA</strong></p></td><td style="vertical-align:top"><p><strong>Action</strong></p></td></tr><tr><td style="vertical-align:top"><p>Treatment week 4: &gt;1000 IU/ml</p></td><td style="vertical-align:top"><p>Discontinue LEVERA, peginterferon alfa and ribavirin</p></td></tr><tr><td style="vertical-align:top"><p>Treatment week 12: &ge;25 IU/ml</p></td><td style="vertical-align:top"><p>Discontinue LEVERA, peginterferon alfa and ribavirin</p></td></tr><tr><td style="vertical-align:top"><p>Treatment week 24: &ge;25 IU/ml</p></td><td style="vertical-align:top"><p>Discontinue peginterferon alfa and ribavirin (treatment with LEVERA is complete at week 24)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><em>Dose recommendation for concomitant medicines</em></p><p><em>&nbsp;</em></p><p><em><u>Strong inhibitors of cytochrome P450 enzyme 3A4 (CYP3A4)</u></em></p><p><em><u>&nbsp;</u></em></p><p>The dose of LEVERA should be reduced to 30 mg once daily when co-administered with strong inhibitors of CYP3A4.</p><p>&nbsp;</p><p><em><u>Moderate inducers of CYP3A4</u></em></p><p>The dose of LEVERA should be increased to 90 mg once daily when co-administered with moderate inducers ofCYP3A4. See section 4.5.</p><p>&nbsp;</p><p><em>Missed doses</em></p><p><em>&nbsp;</em></p><p>Patients should be instructed that, if they miss a dose of LEVERA, the dose should be taken as soon as possible ifremembered within 20 hours of the scheduled dose time. However, if the missed dose is remembered more than 20hours after the scheduled dose, the dose should be skipped and the next dose taken at the appropriate time.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>&nbsp;</p><p>No dose adjustment of LEVERA is required for patients aged &ge;65 years (see section 5.2).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>&nbsp;</p><p>No dose adjustment of LEVERA is required for patients with any degree of renal impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p><em>&nbsp;</em></p><p>No dose adjustment of LEVERA is required for patients with mild (Child-PughA, score 56),moderate (Child-PughB,score 79)or severe (Child-PughC, score &ge;10) hepatic impairment (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of LEVERA in children and adolescents aged below 18 years have not yet been established. Nodata are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>LEVERA is to be taken orally with or without meals. Patients should be instructed to swallow the tablet whole. The film-coatedtablet should not be chewed or crushed due the unpleasant taste of the active substance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Co-administration with medicinal products that strongly induce cytochrome P450 3A4 (CYP3A4) and P-glycoproteintransporter (Pgp)and thus may lead to lower exposure and loss of efficacy of LEVERA. These active substancesinclude but are not limited to phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, rifapentine,systemic dexamethasone, and the herbal product St John's wort (Hypericum perforatum).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LEVERA must not be administered as monotherapy. LEVERA must be administered in combination with other medicinalproducts for the treatment of chronic HCV infection (see sections 4.1 and 4.2).</p><p>&nbsp;</p><p><u>Severe bradycardia and heart block</u></p><p>Cases of severe bradycardia and heart block have been observed when LEVERA is used in combination with sofosbuvirand concomitant amiodarone with or without other drugs that lower heart rate. The mechanism is not established.</p><p>&nbsp;</p><p>The concomitant use of amiodarone was limited through the clinical development of sofosbuvir plus direct-acting antivirals (DAAs). Cases are potentially life threatening, therefore amiodarone should only be used in patients onLEVERA and sofosbuvir when other alternative antiarrhythmic treatments are not tolerated or are contraindicated.</p><p>&nbsp;</p><p>Should concomitant use of amiodarone be considered necessary it is recommended that patients are closely monitoredwhen initiating LEVERA in combination with sofosbuvir. Patients who are identified as being at high risk ofbradyarrhythmia should becontinuously monitored for 48 hours in an appropriate clinical setting.</p><p>&nbsp;</p><p>Due to the long half-life of amiodarone, appropriate monitoring should also be carried out for patients who havediscontinued amiodarone within the past few months and are to be initiated on LEVERA in combination with sofosbuvir.</p><p>&nbsp;</p><p>All patients receiving LEVERA and sofosbuvir in combination with amiodarone with or without other drugs that lowerheart rate should also be warned of the symptoms of bradycardia and heart block and should be advised to seekmedical advice urgently should they experience them.</p><p>&nbsp;</p><p><u>Genotype-specificactivity</u></p><p>Concerning recommended regimens with different HCV genotypes, see section 4.2. Concerning genotype-specificvirological and clinical activity, see section 5.1.</p><p>&nbsp;</p><p>Data to support the treatment of genotype 2 infection with LEVERA and sofosbuvir are limited.</p><p>&nbsp;</p><p>Data from study ALLY3(AI444218) support a 12-weektreatment duration of LEVERA + sofosbuvir for treatment-na&iuml;ve and experiencedpatients with genotype 3 infection without cirrhosis. Lower rates of SVR were observed for patientswith cirrhosis (see section 5.1). Data from compassionate use programmes which included patients with genotype 3infection and cirrhosis, support the use of LEVERA + sofosbuvir for 24 weeks in these patients. The relevance of addingribavirin to that regimen is unclear (see section 5.1).</p><p>&nbsp;</p><p>The clinical data to support the use of LEVERA and sofosbuvir in patients infected with HCV genotypes 4 and 6 arelimited. There are no clinical data in patients with genotype 5 (see section 5.1).</p><p>&nbsp;</p><p><u>Patients with Child-PughC liver disease</u></p><p>The safety and efficacy of LEVERA in the treatment of HCV infection in patients with Child-PughC liver disease havebeen established in the clinical study ALLY1(AI444215, LEVERA + sofosbuvir + ribavirin for 12 weeks) ; however, SVR rates were lower than in patients with Child-PughA and B. Therefore, a conservative treatment regimen of LEVERA +sofosbuvir +/ribavirinfor 24 weeks is proposed for patients with Child-PughC (see sections 4.2 and 5.1). Ribavirinmay be added based on clinical assessment of an individual patient.</p><p>&nbsp;</p><p><u>Retreatment with daclatasvir</u></p><p>The efficacy of LEVERA as part of a retreatment regimen in patients with prior exposure to a NS5A inhibitor has notbeen established.</p><p>&nbsp;</p><p><u>Pregnancy and contraception requirements</u></p><p>LEVERA should not be used during pregnancy or in women of childbearing potential not using contraception. Use ofhighly effective contraception should be continued for 5 weeks after completion of LEVERA therapy (see section 4.6).</p><p>&nbsp;</p><p>When LEVERA is used in combination with ribavirin, the contraindications and warnings for that medicinal product areapplicable. Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed toribavirin; therefore, extreme care must be taken to avoid pregnancy in female patients and in female partners of malepatients (see the Summary of Product Characteristics for ribavirin).</p><p>&nbsp;</p><p><u>HCV/HBV (hepatitis B virus) coinfection</u></p><p>The safety and efficacy of LEVERA in the treatment of HCV infection in patients who are co-infected with HBV have notbeen investigated.</p><p>&nbsp;</p><p><u>Interactions with medicinal products</u></p><p>Co-administration of LEVERA can alter the concentration of other medicinal products and other medicinal products mayalter the concentration of daclatasvir. Refer to section 4.3 for a listing of medicinal products that are contraindicated foruse with LEVERA due to potential loss of therapeutic effect. Refer to section 4.5 for established and other potentiallysignificant drug-druginteractions.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>LEVERA is not recommended for use in children and adolescents aged below 18 years because the safety and efficacyhave not been established in this population.</p><p>&nbsp;</p><p><u>Important information about some of the ingredients in LEVERA</u></p><p>LEVERA contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiencyor glucose-galactosemalabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Contraindications of concomitant use (see section 4.3)</u></p><p>LEVERA is contraindicated in combination with medicinal products that strongly induce CYP3A4 and Pgp,e.g.phenytoin, carbamazepine, oxcarbazepine, phenobarbital,rifampicin, rifabutin, rifapentine, systemic dexamethasone, and the herbal product St John&#39;s wort <em>(Hypericum perforatum)</em>, and thus may lead to lower exposure and loss of efficacyof LEVERA.</p><p>&nbsp;</p><p><u>Potential for interaction with other medicinal products</u></p><p>Daclatasvir is a substrate of CYP3A4, Pgpand organic cation transporter (OCT) 1. Strong or moderate inducers ofCYP3A4 and Pgpmay decrease the plasma levels and therapeutic effect of daclatasvir. Co-administration with stronginducers of CYP3A4 and Pgpis contraindicated while dose adjustment of LEVERA is recommended when</p><p>co-administered with moderate inducers of CYP3A4 and Pgp(see Table 4). Strong inhibitors of CYP3A4 may increase the plasma levels of daclatasvir. Dose adjustment of LEVERA is recommended when co-administered with stronginhibitors of CYP3A4 (see Table 4). Co-administration of medicines that inhibit Pgpor OCT1 activity is likely to have alimited effect on daclatasvir exposure.</p><p>&nbsp;</p><p>Daclatasvir is an inhibitor of Pgp,organic anion transporting polypeptide (OATP) 1B1, OCT1 and breast cancerresistance protein (BCRP). Administration of LEVERA may increase systemic exposure to medicinal products that aresubstrates of Pgp,OATP 1B1, OCT1 or BCRP, which could increase or prolong their therapeutic effect and adverse</p><p>reactions. Caution should be used if the medicinal product has a narrow therapeutic range (see Table 4).</p><p>&nbsp;</p><p>Daclatasvir is a very weak inducer of CYP3A4 and caused a 13% decrease in midazolam exposure. However, as this isa limited effect, dose adjustment of concomitantly administered CYP3A4 substrates is not necessary.</p><p>&nbsp;</p><p>Refer to the respective Summary of Product Characteristics for drug interaction information for other medicinal productsin the regimen.</p><p>&nbsp;</p><p><u>Tabulated summary of interactions</u></p><p>Table 4 provides information from drug interaction studies with daclatasvir including clinical recommendations forestablished or potentially significant drug interactions. Clinically relevant increase in concentration is indicated as &ldquo;&uarr;&rdquo;,clinically relevant decrease as &ldquo;&darr;&rdquo;, no clinically relevant change as &ldquo;&harr;&rdquo;. If available, ratios of geometric means areshown, with 90% confidence intervals (CI) in parentheses. The studies presented in Table 4 were conducted in healthyadult subjects unless otherwise noted. The table is not all-inclusive.</p><p>&nbsp;</p><p><strong>Table 4: Interactions and dose recommendations with other medicinal products</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal products by therapeutic areas</strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning co-administration</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIVIRALS, HCV</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Nucleotide analogue polymerase inhibitor</em></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Sofosbuvir 400 mg once daily</strong></p><p><strong>&nbsp;</strong></p><p>(daclatasvir 60 mg once daily)</p><p>&nbsp;</p><p>Study conducted in patients with chronic HCV infection</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; Daclatasvir*</p><p>&nbsp;</p><p>AUC: 0.95 (0.82, 1.10)</p><p>&nbsp;</p><p>Cmax: 0.88 (0.78, 0.99)</p><p>&nbsp;</p><p>Cmin: 0.91 (0.71, 1.16)</p><p>&nbsp;</p><p>&harr; GS331007**</p><p>&nbsp;</p><p>AUC: 1.0 (0.95, 1.08)</p><p>&nbsp;</p><p>Cmax: 0.8 (0.77, 0.90)</p><p>&nbsp;</p><p>Cmin: 1.4 (1.35, 1.53)</p><p>&nbsp;</p><p>*Comparison for daclatasvir was to a historical reference (data from 3 studies of daclatasvir 60 mg once daily with peginterferon alfa and ribavirin).</p><p>&nbsp;</p><p>**GS331007 is the major circulating metabolite of the prodrug sofosbuvir.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment of LEVERA or sofosbuvir is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Protease inhibitors (PIs)</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Boceprevir</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to CYP3A4 inhibition by boceprevir:</em></p><p><em>&nbsp;</em></p><p>&uarr; Daclatasvir</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>The dose of LEVERA should be reduced to 30 mg once daily when co-administered with boceprevir or other strong inhibitors of CYP3A4.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Simeprevir 150 mg once daily</strong></p><p>&nbsp;</p><p>(daclatasvir 60 mg once daily)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>&uarr; Daclatasvir</p><p>&nbsp;</p><p>AUC: 1.96 (1.84, 2.10)</p><p>&nbsp;</p><p>Cmax: 1.50 (1.39, 1.62)</p><p>&nbsp;</p><p>Cmin: 2.68 (2.42, 2.98)</p><p>&nbsp;</p><p>&uarr; Simeprevir</p><p>&nbsp;</p><p>AUC: 1.44 (1.32, 1.56)</p><p>&nbsp;</p><p>Cmax: 1.39 (1.27, 1.52)</p><p>&nbsp;</p><p>Cmin: 1.49 (1.33, 1.67)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>No dose adjustment of LEVERA or simeprevir is required.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Telaprevir 500 mg q12h</strong></p><p>(daclatasvir 20 mg once daily)</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Telaprevir 750 mg q8h</strong></p><p>(daclatasvir 20 mg once daily)</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&uarr; Daclatasvir</p><p>&nbsp;</p><p>AUC: 2.32 (2.06, 2.62)</p><p>&nbsp;</p><p>Cmax: 1.46 (1.28, 1.66)</p><p>&nbsp;</p><p>&harr; Telaprevir</p><p>&nbsp;</p><p>AUC: 0.94 (0.84, 1.04)</p><p>&nbsp;</p><p>Cmax: 1.01 (0.89, 1.14)</p><p>&nbsp;</p><p>&nbsp;</p><p>&uarr; Daclatasvir</p><p>&nbsp;</p><p>AUC: 2.15 (1.87, 2.48)</p><p>&nbsp;</p><p>Cmax: 1.22 (1.04, 1.44)</p><p>&nbsp;</p><p>&harr; Telaprevir</p><p>&nbsp;</p><p>AUC: 0.99 (0.95, 1.03)</p><p>&nbsp;</p><p>Cmax: 1.02 (0.95, 1.09)</p><p>&nbsp;</p><p>CYP3A4 inhibition by telaprevir</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>The dose of LEVERA should be reduced to 30 mg once daily when co-administered with telaprevir or other strong inhibitors of CYP3A4.</p></td></tr><tr><td style="vertical-align:top"><p><em>Other HCV antivirals</em></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Peginterferon alfa 180 &mu;g once weekly and ribavirin 1000 mg or 1200 mg/day</strong></p><p><strong>in two divided doses</strong></p><p>&nbsp;</p><p>(daclatasvir 60 mg once daily)</p><p>&nbsp;</p><p>Study conducted in patients with chronic HCV infection</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>AUC: &harr;*</p><p>&nbsp;</p><p>Cmax: &harr;*</p><p>Cmin: &harr;*</p><p>&nbsp;</p><p>&harr; Peginterferon alfa</p><p>&nbsp;</p><p>Cmin: &harr;*</p><p>&nbsp;</p><p>&harr; Ribavirin</p><p>&nbsp;</p><p>AUC: 0.94 (0.80, 1.11)</p><p>&nbsp;</p><p>Cmax: 0.94 (0.79, 1.11)</p><p>&nbsp;</p><p>Cmin: 0.98 (0.82, 1.17)</p><p>&nbsp;</p><p>*PK parameters for daclatasvir when</p><p>administered with peginterferon alfa and</p><p>ribavirin in this study were similar to those observed in a study of HCV-infected</p><p>subjects administered</p><p>daclatasvir monotherapy for 14 days.</p><p>PK trough levels for peginterferon alfa in</p><p>patients who received peginterferon alfa, ribavirin, and daclatasvir were similar to those in patients who received peginterferon alfa, ribavirin, and placebo.</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>No dose adjustment of LEVERA, peginterferon alfa, or ribavirin is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIVIRALS, HIV or HBV</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Protease inhibitors (PIs)</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Atazanavir 300 mg/ritonavir 100 mg once daily</strong></p><p><strong>&nbsp;</strong></p><p>(daclatasvir 20 mg once daily)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>&uarr; Daclatasvir</p><p>&nbsp;</p><p>AUC*: 2.10 (1.95, 2.26)</p><p>&nbsp;</p><p>Cmax*: 1.35 (1.24, 1.47)</p><p>&nbsp;</p><p>Cmin*: 3.65 (3.25, 4.11)</p><p>&nbsp;</p><p>CYP3A4 inhibition by ritonavir</p><p>*results are dose-normalized</p><p>to 60 mg dose.</p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>The dose of LEVERA should be reduced to 30 mg once daily when co-administered with atazanavir/ritonavir,</p><p>atazanavir/cobicistat or other</p><p>strong inhibitors of CYP3A4.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Atazanavir/cobicistat</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Interaction not studied.</p><p>&nbsp;</p><p><em>Expected due to CYP3A4 inhibition by atazanavir/cobicistat:</em></p><p>&nbsp;</p><p>&uarr; Daclatasvir</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Darunavir 800 mg/ritonavir 100 mg once daily</strong></p><p>&nbsp;</p><p>(daclatasvir 30 mg once daily)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>AUC: 1.41 (1.32, 1.50)</p><p>&nbsp;</p><p>Cmax: 0.77 (0.70, 0.85)</p><p>&nbsp;</p><p>&harr; Darunavir</p><p>&nbsp;</p><p>AUC: 0.90 (0.73, 1.11)</p><p>&nbsp;</p><p>Cmax: 0.97 (0.80, 1.17)</p><p>&nbsp;</p><p>Cmin: 0.98 (0.67, 1.44)</p></td><td rowspan="2" style="vertical-align:top"><p>No dose adjustment of LEVERA 60 mg once daily,</p><p>darunavir/ritonavir (800/100 mg once daily or 600/100 mg twice daily) or darunavir/cobicistat is required.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Darunavir/cobicistat</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected:</em></p><p>&nbsp;</p><p>&harr; Daclatasvir</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Lopinavir 400 mg/ritonavir 100 mg twice daily</strong></p><p>&nbsp;</p><p>(daclatasvir 30 mg once daily)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>AUC: 1.15 (1.07, 1.24)</p><p>&nbsp;</p><p>Cmax: 0.67 (0.61, 0.74)</p><p>&nbsp;</p><p>&harr; Lopinavir*</p><p>&nbsp;</p><p>AUC: 1.15 (0.77, 1.72)</p><p>&nbsp;</p><p>Cmax: 1.22 (1.06, 1.41)</p><p>&nbsp;</p><p>Cmin: 1.54 (0.46, 5.07)</p><p>&nbsp;</p><p>* the effect of 60 mg daclatasvir on lopinavir may be higher.</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>No dose adjustment of LEVERA 60 mg once daily or</p><p>lopinavir/ritonavir is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Tenofovir disoproxil fumarate 300 mg once daily</strong></p><p>&nbsp;</p><p>(daclatasvir 60 mg once daily)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>&nbsp;</p><p>AUC: 1.10 (1.01, 1.21)</p><p>&nbsp;</p><p>Cmax: 1.06 (0.98, 1.15)</p><p>&nbsp;</p><p>Cmin: 1.15 (1.02, 1.30)</p><p>&nbsp;</p><p>&harr; Tenofovir</p><p>&nbsp;</p><p>AUC: 1.10 (1.05, 1.15)</p><p>&nbsp;</p><p>Cmax: 0.95 (0.89, 1.02)</p><p>&nbsp;</p><p>Cmin: 1.17 (1.10, 1.24)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>No dose adjustment of LEVERA or tenofovir is required.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Lamivudine</strong></p><p><strong>&nbsp;</strong></p><p><strong>Zidovudine</strong></p><p><strong>&nbsp;</strong></p><p><strong>Emtricitabine</strong></p><p><strong>&nbsp;</strong></p><p><strong>Abacavir</strong></p><p><strong>&nbsp;</strong></p><p><strong>Didanosine</strong></p><p><strong>&nbsp;</strong></p><p><strong>Stavudine</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected:</em></p><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>&harr; NRTI</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>No dose adjustment of LEVERA or the NRTI is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Nonnucleoside reverse transcriptase inhibitors (NNRTIs)</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Efavirenz 600 mg once daily</strong></p><p><strong>&nbsp;</strong></p><p>(daclatasvir 60 mg once daily/120 mg once daily)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>&darr; Daclatasvir</p><p>&nbsp;</p><p>&nbsp;</p><p>AUC*: 0.68 (0.60, 0.78)</p><p>&nbsp;</p><p>Cmax*: 0.83 (0.76, 0.92)</p><p>&nbsp;</p><p>Cmin*: 0.41 (0.34, 0.50)</p><p>&nbsp;</p><p>Induction of CYP3A4 by efavirenz</p><p>&nbsp;</p><p>*results are dose-normalized</p><p>to 60 mg</p><p>dose.</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>The dose of LEVERA should be increased to 90 mg once daily when co-administered with efavirenz.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Etravirine</strong></p><p><strong>&nbsp;</strong></p><p><strong>Nevirapine</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to CYP3A4 induction by etravirine or nevirapine:</em></p><p><em>&nbsp;</em></p><p>&darr; Daclatasvir</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Due to the lack of data,</p><p>co-administration of LEVERA and etravirine or nevirapine is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Rilpivirine</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Interaction not studied.</p><p>&nbsp;</p><p><em>Expected:</em></p><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>&harr; Rilpivirine</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>No dose adjustment of LEVERA or rilpivirine is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Integrase inhibitors</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Dolutegravir 50 mg once daily</strong></p><p><strong>&nbsp;</strong></p><p>(daclatasvir 60 mg once daily)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>AUC: 0.98 (0.83, 1.15)</p><p>&nbsp;</p><p>Cmax: 1.03 (0.84, 1.25)</p><p>&nbsp;</p><p>Cmin: 1.06 (0.88, 1.29)</p><p>&nbsp;</p><p>&uarr; Dolutegravir</p><p>&nbsp;</p><p>AUC: 1.33 (1.11, 1.59)</p><p>&nbsp;</p><p>Cmax: 1.29 (1.07, 1.57)</p><p>&nbsp;</p><p>Cmin: 1.45 (1.25, 1.68)</p><p>&nbsp;</p><p>Inhibition of Pgp and BCRP by daclatasvir</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>No dose adjustment of LEVERA or dolutegravir is required.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Raltegravir</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Interaction not studied.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>Expected:</em></p><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>&harr; Raltegravir</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>No dose adjustment of LEVERA or raltegravir is required.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Interaction not studied for this fixeddose combination tablet.</p><p><em>&nbsp;</em></p><p><em>Expected due to CYP3A4 inhibition bycobicistat:</em></p><p><em>&nbsp;</em></p><p>&uarr; Daclatasvir</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>The dose of LEVERA should be reduced to 30 mg once daily when co-administered with cobicistat or other strong inhibitors of CYP3A4.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Fusion inhibitor</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Enfuvirtide</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected:</em></p><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>&harr; Enfuvirtide</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment of LEVERA or enfuvirtide is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>CCR5 receptor antagonist</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Maraviroc</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected:</em></p><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>&harr; Maraviroc</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment of LEVERA or maraviroc is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ACID REDUCING AGENTS</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>H2-receptor antagonists</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Famotidine 40 mg single dose</strong></p><p><strong>&nbsp;</strong></p><p>(daclatasvir 60 mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>AUC: 0.82 (0.70, 0.96)</p><p>&nbsp;</p><p>Cmax: 0.56 (0.46, 0.67)</p><p>&nbsp;</p><p>Cmin: 0.89 (0.75, 1.06)</p><p>&nbsp;</p><p>Increase in gastric pH</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment of LEVERA is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Proton pump inhibitors</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Omeprazole 40 mg once daily</strong></p><p>&nbsp;</p><p>(daclatasvir 60 mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>AUC: 0.84 (0.73, 0.96)</p><p>&nbsp;</p><p>Cmax: 0.64 (0.54, 0.77)</p><p>&nbsp;</p><p>Cmin: 0.92 (0.80, 1.05)</p><p>&nbsp;</p><p>Increase in gastric pH</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment of LEVERA is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIBACTERIALS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Clarithromycin</strong></p><p><strong>&nbsp;</strong></p><p><strong>Telithromycin</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to CYP3A4 inhibition bythe antibacterial:</em></p><p><em>&nbsp;</em></p><p>&uarr; Daclatasvir</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>The dose of LEVERA should be reduced to 30 mg once daily when co-administered with clarithromycin, telithromycin or other strong inhibitors of CYP3A4.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Erythromycin</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to CYP3A4 inhibition bythe antibacterial:</em></p><p>&nbsp;</p><p>&uarr; Daclatasvir</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Administration of LEVERA with erythromycin may result in increased concentrations of</p><p>daclatasvir. Caution is advised.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Azithromycin</strong></p><p><strong>&nbsp;</strong></p><p><strong>Ciprofloxacin</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected:</em></p><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>&harr; Azithromycin or Ciprofloxacin</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment of LEVERA or azithromycin or ciprofloxacin is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTICOAGULANTS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Dabigatran etexilate</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to inhibition of Pgp by daclatasvir:</em></p><p><em>&nbsp;</em></p><p>&uarr; Dabigatran etexilate</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Safety monitoring is advised when initiating treatment with LEVERA in patients receiving dabigatran etexilate or other intestinal Pgp substrates that have a narrow therapeutic range.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Warfarin</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected:</em></p><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>&harr; Warfarin</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment of LEVERA or warfarin is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTICONVULSANTS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Carbamazepine</strong></p><p><strong>&nbsp;</strong></p><p><strong>Oxcarbazepine</strong></p><p><strong>&nbsp;</strong></p><p><strong>Phenobarbital</strong></p><p><strong>&nbsp;</strong></p><p><strong>Phenytoin</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to CYP3A4 induction by the anticonvulsant:</em></p><p>&nbsp;</p><p>&darr; Daclatasvir</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Co-administration of LEVERA with carbamazepine, oxcarbazepine, phenobarbital, phenytoin or other strong inducers of CYP3A4 is contraindicated (see section 4.3).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIDEPRESSANTS</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Selective serotonin reuptake inhibitors</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Escitalopram 10 mg once daily</strong></p><p><strong>&nbsp;</strong></p><p>(daclatasvir 60 mg once daily)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>AUC: 1.12 (1.01, 1.26)</p><p>&nbsp;</p><p>Cmax: 1.14 (0.98, 1.32)</p><p>&nbsp;</p><p>Cmin: 1.23 (1.09, 1.38)</p><p>&nbsp;</p><p>&harr;Escitalopram</p><p>&nbsp;</p><p>AUC: 1.05 (1.02, 1.08)</p><p>&nbsp;</p><p>Cmax: 1.00 (0.92, 1.08)</p><p>&nbsp;</p><p>Cmin: 1.10 (1.04, 1.16)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment of LEVERA or escitalopram is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIFUNGALS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Ketoconazole 400 mg once daily</strong></p><p>&nbsp;</p><p>(daclatasvir 10 mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&uarr; Daclatasvir</p><p>&nbsp;</p><p>AUC: 3.00 (2.62, 3.44)</p><p>&nbsp;</p><p>Cmax: 1.57 (1.31, 1.88)</p><p>&nbsp;</p><p>CYP3A4 inhibition by</p><p>Ketoconazole</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>The dose of LEVERA should be reduced to 30 mg once daily when co-administered with ketoconazole or other strong inhibitors of CYP3A4.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Itraconazole</strong></p><p><strong>&nbsp;</strong></p><p><strong>Posaconazole</strong></p><p><strong>&nbsp;</strong></p><p><strong>Voriconazole</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to CYP3A4 inhibition by the antifungal:</em></p><p><em>&nbsp;</em></p><p>&uarr; Daclatasvir</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Fluconazole</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to CYP3A4 inhibition by the antifungal:</em></p><p><em>&nbsp;</em></p><p>&uarr; Daclatasvir</p><p>&nbsp;</p><p>&harr; Fluconazole</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Modest increases in</p><p>concentrations of daclatasvir are expected, but no dose adjustment of LEVERA or fluconazole is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIMYCOBACTERIALS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Rifampicin 600 mg once daily</strong></p><p><strong>&nbsp;</strong></p><p>(daclatasvir 60 mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&darr; Daclatasvir</p><p>&nbsp;</p><p>AUC: 0.21 (0.19, 0.23)</p><p>&nbsp;</p><p>Cmax: 0.44 (0.40, 0.48)</p><p>&nbsp;</p><p>CYP3A4 induction by</p><p>rifampicin</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>Co-administration of LEVERA with rifampicin, rifabutin, rifapentine or other strong inducers of CYP3A4 is contraindicated (see section</p><p>4.3).</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Rifabutin</strong></p><p><strong>&nbsp;</strong></p><p><strong>Rifapentine</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>nteraction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to CYP3A4 induction by the anti-mycobacterial:</em></p><p><em>&nbsp;</em></p><p>&darr; Daclatasvir</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>CARDIOVASCULAR AGENTS</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Antiarrhythmics</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Digoxin 0.125 mg once daily</strong></p><p>&nbsp;</p><p>(daclatasvir 60 mg once daily)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&uarr; Digoxin</p><p>&nbsp;</p><p>AUC: 1.27 (1.20, 1.34)</p><p>&nbsp;</p><p>Cmax: 1.65 (1.52, 1.80)</p><p>&nbsp;</p><p>Cmin: 1.18 (1.09, 1.28)</p><p>&nbsp;</p><p>Pgp inhibition by daclatasvir</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Digoxin should be used with</p><p>caution when co-administered with LEVERA. The lowest dose of digoxin should be initially prescribed. The serum digoxin concentrations should be monitored and used for titration of digoxin dose to obtain the desired clinical effect.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Amiodarone</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use only if no otheralternative is available. Close monitoring is recommended if this medicinal product is administered with LEVERA in combination with sofosbuvir (see sections 4.4 and 4.8).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Calcium channel blockers</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Diltiazem</strong></p><p><strong>&nbsp;</strong></p><p><strong>Nifedipine</strong></p><p><strong>&nbsp;</strong></p><p><strong>Amlodipine</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to CYP3A4 inhibition by the calcium channel blocker:</em></p><p><em>&nbsp;</em></p><p>&uarr; Daclatasvir</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Administration of LEVERA with any of these calcium channel blockers may result in increased concentrations of daclatasvir. Caution is advised.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Verapamil</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to CYP3A4 and Pgp inhibition by verapamil:</em></p><p><em>&nbsp;</em></p><p>&uarr; Daclatasvir</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Administration of LEVERA with verapamil may result in increased concentrations of daclatasvir. Caution is advised.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>CORTICOSTEROIDS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Systemic dexamethasone</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to CYP3A4 induction by dexamethasone:</em></p><p>&nbsp;</p><p>&darr; Daclatasvir</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Co-administration of LEVERA with systemic dexamethasone or other strong inducers of CYP3A4 is</p><p>contraindicated (see section 4.3).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HERBAL SUPPLEMENTS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>St. John&#39;s wort (</strong><strong><em>Hypericum perforatum)</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to CYP3A4 induction by St. John&#39;s wort:</em></p><p>&nbsp;</p><p>&darr; Daclatasvir</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Co-administration of LEVERA with St. John&#39;s wort or other strong inducers of CYP3A4 is</p><p>contraindicated (see section 4.3).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HORMONAL CONTRACEPTIVES</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Ethinylestradiol 35 &mu;g once daily for 21 days + norgestimate</strong></p><p><strong>0.180/0.215/0.250 mg once daily for 7/7/7 days</strong></p><p><strong>&nbsp;</strong></p><p>(daclatasvir 60 mg once daily)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; Ethinylestradiol</p><p>&nbsp;</p><p>AUC: 1.01 (0.95, 1.07)</p><p>&nbsp;</p><p>Cmax: 1.11 (1.02, 1.20)</p><p>&nbsp;</p><p>&harr; Norelgestromin</p><p>&nbsp;</p><p>AUC: 1.12 (1.06, 1.17)</p><p>&nbsp;</p><p>Cmax: 1.06 (0.99, 1.14)</p><p>&nbsp;</p><p>&harr; Norgestrel</p><p>&nbsp;</p><p>AUC: 1.12 (1.02, 1.23)</p><p>&nbsp;</p><p>Cmax: 1.07 (0.99, 1.16)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>An oral contraceptive containing ethinylestradiol 35 &mu;g and norgestimate 0.180/0.215/0.250 mg is recommended with LEVERA. Other oral contraceptives have not been studied.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>IMMUNOSUPPRESSANTS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Cyclosporine 400 mg single dose</strong></p><p>&nbsp;</p><p>(daclatasvir 60 mg once daily)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>AUC: 1.40 (1.29, 1.53)</p><p>&nbsp;</p><p>Cmax: 1.04 (0.94, 1.15)</p><p>&nbsp;</p><p>Cmin: 1.56 (1.41, 1.71)</p><p>&nbsp;</p><p>&harr; Cyclosporine</p><p>&nbsp;</p><p>AUC: 1.03 (0.97, 1.09)</p><p>&nbsp;</p><p>Cmax: 0.96 (0.91, 1.02)</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment of either</p><p>medicinal product is required when LEVERA is co-administered with</p><p>cyclosporine, tacrolimus,</p><p>sirolimus or mycophenolate</p><p>mofetil.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Tacrolimus 5 mg single dose</strong></p><p>&nbsp;</p><p>(daclatasvir 60 mg once daily)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>AUC: 1.05 (1.03, 1.07)</p><p>&nbsp;</p><p>Cmax: 1.07 (1.02, 1.12)</p><p>&nbsp;</p><p>Cmin: 1.10 (1.03, 1.19)</p><p>&nbsp;</p><p>&harr; Tacrolimus</p><p>&nbsp;</p><p>AUC: 1.00 (0.88, 1.13)</p><p>&nbsp;</p><p>Cmax: 1.05 (0.90, 1.23)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Sirolimus</strong></p><p><strong>&nbsp;</strong></p><p><strong>Mycophenolate mofetil</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected:</em></p><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>&harr; Immunosuppressant</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>LIPID LOWERING AGENTS</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>HMG-CoA reductase inhibitors</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Rosuvastatin 10 mg single dose</strong></p><p>&nbsp;</p><p>(daclatasvir 60 mg once daily)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&uarr; Rosuvastatin</p><p>&nbsp;</p><p>AUC: 1.58 (1.44, 1.74)</p><p>&nbsp;</p><p>Cmax: 2.04 (1.83, 2.26)</p><p>&nbsp;</p><p>Inhibition of OATP 1B1 and BCRP by daclatasvir</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>Caution should be used when</p><p>LEVERA is co-administered with rosuvastatin or other substrates of OATP 1B1 or BCRP.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Atorvastatin</strong></p><p><strong>&nbsp;</strong></p><p><strong>Fluvastatin</strong></p><p><strong>&nbsp;</strong></p><p><strong>Simvastatin</strong></p><p><strong>&nbsp;</strong></p><p><strong>Pitavastatin</strong></p><p><strong>&nbsp;</strong></p><p><strong>Pravastatin</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected due to inhibition of OATP 1B1 and/or BCRP by daclatasvir:</em></p><p><em>&nbsp;</em></p><p>&uarr; Concentration of statin</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>NARCOTIC ANALGESICS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Buprenorphine/naloxone, 8/2 mg to 24/6 mg once daily individualized dose*</strong></p><p>&nbsp;</p><p>(daclatasvir 60 mg once daily)</p><p>&nbsp;</p><p>&nbsp;</p><p>* Evaluated in opioid-dependent adults</p><p>on stable buprenorphine/naloxone</p><p>maintenance therapy.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>AUC: &harr;*</p><p>&nbsp;</p><p>Cmax: &harr;*</p><p>&nbsp;</p><p>Cmin: &harr;*</p><p>&nbsp;</p><p>&uarr; Buprenorphine</p><p>&nbsp;</p><p>AUC: 1.37 (1.24, 1.52)</p><p>&nbsp;</p><p>Cmax: 1.30 (1.03, 1.64)</p><p>&nbsp;</p><p>Cmin: 1.17 (1.03, 1.32)</p><p>&nbsp;</p><p>&uarr; Norbuprenorphine</p><p>&nbsp;</p><p>AUC: 1.62 (1.30, 2.02)</p><p>&nbsp;</p><p>Cmax: 1.65 (1.38, 1.99)</p><p>&nbsp;</p><p>Cmin: 1.46 (1.12, 1.89)</p><p>&nbsp;</p><p>*Compared to historical data.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment of LEVERA or buprenorphine may be required, but it is recommended that patients should be monitored for signs of opiate toxicity.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Methadone, 40-120 mg once daily individualized dose*</strong></p><p><strong>&nbsp;</strong></p><p><strong>(daclatasvir 60 mg once daily)</strong></p><p><strong>&nbsp;</strong></p><p><strong>* Evaluated in opioid-dependent adults on stable methadone maintenance</strong></p><p><strong>therapy.</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; Daclatasvir</p><p>&nbsp;</p><p>AUC: &harr;*</p><p>&nbsp;</p><p>Cmax: &harr;*</p><p>&nbsp;</p><p>Cmin: &harr;*</p><p>&nbsp;</p><p>&harr; Rmethadone</p><p>&nbsp;</p><p>AUC: 1.08 (0.94, 1.24)</p><p>&nbsp;</p><p>Cmax: 1.07 (0.97, 1.18)</p><p>&nbsp;</p><p>Cmin: 1.08 (0.93, 1.26)</p><p>&nbsp;</p><p>*Compared to historical data.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment of LEVERA or methadone is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>SEDATIVES</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Benzodiazepines</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Midazolam 5 mg single dose</strong></p><p>&nbsp;</p><p>(daclatasvir 60 mg once daily)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; Midazolam</p><p>&nbsp;</p><p>AUC: 0.87 (0.83, 0.92)</p><p>&nbsp;</p><p>Cmax: 0.95 (0.88, 1.04)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment of</p><p>midazolam, other</p><p>benzodiazepines or other CYP3A4 substrates is required when co-administered with LEVERA.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Triazolam</strong></p><p><strong>&nbsp;</strong></p><p><strong>Alprazolam</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interaction not studied.</p><p><em>&nbsp;</em></p><p><em>Expected:</em></p><p>&nbsp;</p><p>&harr; Triazolam</p><p>&nbsp;</p><p>&harr; Alprazolam</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>No clinically relevant effects on the pharmacokinetics of either medicinal product are expected when daclatasvir isco-administered with any of the following: PDE5inhibitors, medicinal products in the ACE inhibitor class (e.g. enalapril),medicinal products in the angiotensin II receptor antagonist class (e.g. losartan, irbesartan, olmesartan, candesartan,</p><p>valsartan), disopyramide, propafenone, flecainide, mexilitine, quinidine or antacids.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no data from the use of daclatasvir in pregnant women.</p><p>&nbsp;</p><p>Studies of daclatasvir in animals have shown embryotoxic and teratogenic effects (see section 5.3). The potential riskfor humans is unknown.</p><p>&nbsp;</p><p>LEVERA should not be used during pregnancy or in women of childbearing potential not using contraception (seesection 4.4). Use of highly effective contraception should be continued for 5 weeks after completion of LEVERA therapy(see section 4.5).</p><p>&nbsp;</p><p>Since LEVERA is used in combination with other agents, the contraindications and warnings for those medicinalproducts are applicable.</p><p>&nbsp;</p><p>For detailed recommendations regarding pregnancy and contraception, refer to the Summary of Product Characteristicsfor ribavirin and peginterferon alfa.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is not known whether daclatasvir is excreted in human milk. Availablepharmacokinetic and toxicological data in animals have shown excretion of daclatasvir and metabolites in milk (see section 5.3). A risk to the newborn/infantcannot be excluded. Mothers should be instructed not to breastfeed if they are taking LEVERA.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No human data on the effect of daclatasvir on fertility are available.</p><p>&nbsp;</p><p>In rats, no effect on mating or fertility was seen (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dizziness has been reported during treatment with LEVERA in combination withsofosbuvir, and dizziness, disturbance in attention, blurred vision and reduced visual acuity have been reported during treatment with LEVERA in combinationwith peginterferon alfa and ribavirin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The overall safety profile of daclatasvir is based on data from 2215 patients with chronic HCV infection who receivedLEVERA once daily either in combination with sofosbuvir with or without ribavirin (n=679, pooled data) or in combinationwith peginterferon alfa and ribavirin (n=1536, pooled data) from a total of 14 clinical studies.</p><p>&nbsp;</p><p><em>LEVERA in combination with sofosbuvir</em></p><p><em>&nbsp;</em></p><p>The most frequently reported adverse reactions were fatigue, headache, and nausea. Grade 3 adverse reactions werereported in less than 1% of patients, and no patients had a Grade 4 adverse reaction. Four patients discontinued theLEVERA regimen for adverse events, only one of which was considered related to study therapy.</p><p>&nbsp;</p><p><em>LEVERA in combination with peginterferon alfa and ribavirin</em></p><p><em>&nbsp;</em></p><p>The most frequently reported adverse reactions were fatigue, headache, pruritus, anaemia, influenza-likeillness,nausea, insomnia, neutropenia, asthenia, rash, decreased appetite, dry skin, alopecia, pyrexia, myalgia, irritability,cough, diarrhoea, dyspnoea andarthralgia. The most frequently reported adverse reactions of at least Grade 3 severity</p><p>(frequency of 1% or greater) were neutropenia, anaemia, lymphopenia and thrombocytopenia. The safety profile of daclatasvir in combination with peginterferon alfa and ribavirin was similar to that seen with peginterferon alfa andribavirin alone, including among patients with cirrhosis.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions are listed in Table 5 by regimen, system organ class and frequency: very common (&ge;1/10), common(&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000). Within eachfrequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 5: Adverse reactions in clinical studies</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><em>LEVERA +sofosbuvir + ribavirin</em></p><p><em>N=203</em></p></td><td style="vertical-align:top"><p><em>LEVERA +sofosbuvir</em></p><p><em>N=476</em></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>anaemia</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>decreased appetite</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>insomnia, irritability</p></td><td style="vertical-align:top"><p>insomnia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>dizziness, migraine</p></td><td style="vertical-align:top"><p>dizziness, migraine</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>hot flush</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>dyspnoea, dyspnoea exertional, cough, nasal congestion</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>nausea</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>diarrhoea, vomiting, abdominal pain, gastro-oesophageal reflux</p><p>disease, constipation, dry mouth, flatulence</p></td><td style="vertical-align:top"><p>nausea, diarrhoea, abdominal pain</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>rash, alopecia, pruritus, dry skin</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>arthralgia, myalgia</p></td><td style="vertical-align:top"><p>arthralgia, myalgia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>fatigue</p></td><td style="vertical-align:top"><p>fatigue</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em>Laboratory abnormalities</em></p><p><em>&nbsp;</em></p><p>In clinical studies of LEVERA in combination with sofosbuvir with or without ribavirin, 2% of patients had Grade 3haemoglobin decreases; all of these patients receivedLEVERA + sofosbuvir + ribavirin. Grade 3/4 increases in total bilirubin were observed in 5% of patients (all in patients with HIV coinfectionwho were receiving concomitant</p><p>atazanavir, with Child-PughA, B, or C cirrhosis, or who were post-livertransplant).</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>Cardiac arrhythmias</em></p><p>&nbsp;</p><p>Cases of severe bradycardia and heart block have been observed when LEVERA is used in combination with sofosbuvirand concomitant amiodarone and/or other drugs that lower heart rate (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety and efficacy of LEVERA in children and adolescents aged &lt;18 years have not yet been established. No dataare available.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continuedmonitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited experience of accidental overdose of daclatasvir in clinical studies. In phase 1 clinical studies, healthysubjects who received up to 100 mg once daily for up to 14 days or single doses up to 200 mg had no unexpectedadverse reactions.</p><p>&nbsp;</p><p>There is no known antidote for overdose of daclatasvir. Treatment of overdose with daclatasvir should consist of generalsupportive measures, including monitoring of vital signs, and observation of the patient&#39;s clinical status. Becausedaclatasvir is highly protein bound (99%) and has a molecular weight &gt;500, dialysis is unlikely to significantly reduce</p><p>plasma concentrations of daclatasvir.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Direct-actingantiviral, ATC code: J05AX14</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Daclatasvir is an inhibitor of nonstructural protein 5A (NS5A), a multifunctional protein that is an essential component ofthe HCV replication complex. Daclatasvir inhibits both viral RNA replication and virion assembly.</p><p>&nbsp;</p><p><u>Antiviral activity in cell culture</u></p><p>Daclatasvir is an inhibitor of HCV genotypes 1a and 1b replication in cell-based</p><p>replicon assays with effectiveconcentration (50% reduction, EC50) values of 0.003-0.050and 0.001-0.009nM, respectively, depending on the assaymethod. The daclatasvir EC50 values in the replicon system were 0.003-1.25nM for genotypes 3a, 4a, 5a and 6a, and0.034-19nM for genotype 2a as well as 0.020 nM for infectious genotype 2a (JFH1)</p><p>virus.</p><p>&nbsp;</p><p>Daclatasvir showed additive to synergistic interactions with interferon alfa, HCV nonstructural protein 3 (NS3) PIs, HCVnonstructural protein 5B (NS5B) nonnucleoside</p><p>inhibitors, and HCV NS5B nucleoside analogues in combination studiesusing the cell-basedHCV replicon system. No antagonism of antiviral activity was observed.</p><p>&nbsp;</p><p>No clinically relevant antiviral activity was observed against a variety of RNA and DNA viruses, including HIV,confirming that daclatasvir, which inhibits a HCV-specific</p><p>target, is highly selective for HCV.</p><p>&nbsp;</p><p><u>Resistance in cell culture</u></p><p>Substitutions conferring daclatasvir resistance in genotypes 14were observed in the N-terminal100 amino acid regionof NS5A in a cell-basedreplicon system. L31V and Y93H were frequently observed resistance substitutions in genotype1b, while M28T, L31V/M, Q30E/H/R, and Y93C/H/N were frequently observed resistance substitutions in genotype 1a.These substitutions conferred low level resistance (EC50 &lt;1 nM) for genotype 1b, and higher levels of resistance forgenotype 1a (EC50 up to 350 nM). The most resistant variants with single amino acid substitution in genotype 2a andgenotype 3a were F28S (EC50 &gt;300 nM) and Y93H (EC50 &gt;1,000 nM), respectively. In genotype 4, amino acidsubstitutions at 30 and 93 (EC50 &lt; 16 nM) were frequently selected.</p><p>&nbsp;</p><p><em>Cross-resistance</em></p><p><em>&nbsp;</em></p><p>HCV replicons expressing daclatasvir-associatedresistance substitutions remained fully sensitive to interferon alfa andother anti-HCVagents with different mechanisms of action, such as NS3 protease and NS5B polymerase (nucleosideand nonnucleoside)</p><p>inhibitors.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>In clinical studies of daclatasvir in combination with sofosbuvir or with peginterferon alfa and ribavirin, plasma HCV RNAvalues were measured using the COBAS TaqMan HCV test (version 2.0), for use with the High Pure System, with alower limit of quantification (LLOQ) of 25 IU/ ml. SVR was the primary endpoint to determine the HCV cure rate, whichwas defined as HCV RNA less than LLOQ at 12 weeks after the end of treatment (SVR12) for studies AI444040, ALLY1(AI444215), ALLY2(AI444216), ALLY3</p><p>(AI444218), AI444042 and AI444043 and as HCV RNA undetectable at 24weeks after the end of treatment (SVR24) for study AI444010.</p><p><em>&nbsp;</em></p><p><em>Daclatasvir in combination with sofosbuvir</em></p><p><em>&nbsp;</em></p><p>The efficacy and safety of daclatasvir 60 mg once daily in combination with sofosbuvir 400 mg once daily in thetreatment of patients with chronic HCV infection wereevaluated in four open-label studies (AI444040, ALLY1,ALLY2and ALLY3).</p><p>&nbsp;</p><p>In study AI444040, 211 adults with HCV genotype 1, 2, or 3 infection and without cirrhosis received daclatasvir andsofosbuvir, with or without ribavirin. Among the 167 patients with HCV genotype 1 infection, 126 were treatment-na&iuml;veand 41 had failed prior therapy with a PI regimen (boceprevir or telaprevir). All 44 patients with HCV genotype 2 (n=26)or 3 (n=18) infection were treatment-na&iuml;ve.Treatment duration was 12 weeks for 82 treatment-na&iuml;veHCV genotype 1patients, and 24 weeks for all otherpatients in the study. The 211 patients had a median age of 54 years (range: 20 to 70) ;83% were white; 12% were black/African-American; 2% were Asian; 20% were Hispanic or Latino. The mean scoreon the FibroTest (a validated noninvasivediagnostic assay) was 0.460 (range: 0.03 to 0.89). Conversion of theFibroTest score to the corresponding METAVIR score suggests that 35% of all patients (49% of patients with prior PIfailure, 30% of patients with genotype 2 or 3) had &ge;F3 liver fibrosis. Most patients (71%, including 98% of prior PI failures) had IL28Brs12979860 non-CCgenotypes.</p><p>&nbsp;</p><p>SVR12 was achieved by 99% patients with HCV genotype 1, 96% of those withgenotype 2 and 89% of those with genotype 3 (see Tables 6 and 7). Response was rapid (viral load at Week 4 showed that more than 97% of patientsresponded to therapy), and was not influenced by HCV subtype (1a/1b), IL28B genotype, or use of ribavirin. Among</p><p>treatment-na&iuml;vepatients with HCV RNA results at both follow-upWeeks 12 and 24, concordance between SVR12 andSVR24 was 99.5% independent of treatment duration.</p><p>&nbsp;</p><p>Treatment-na&iuml;vepatients with HCV genotype 1 who received 12 weeks of treatment had a similar response as thosetreated for 24 weeks (Table 6).</p><p>&nbsp;</p><p><strong>Table 6: Treatment outcomes, daclatasvir in combination with sofosbuvir, HCV genotype 1 in Study AI444040</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Treatment-na&iuml;ve</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Prior telaprevir or boceprevir failures</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>daclatasvir </strong><strong>+ sofosbuvir</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=70</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>daclatasvir</strong><strong> +</strong></p><p><strong>sofosbuvir +</strong></p><p><strong>ribavirin</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=56</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>All</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=126</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>daclatasvir +</strong></p><p><strong>sofosbuvir</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=21</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>daclatasvir +</strong></p><p><strong>sofosbuvir +</strong></p><p><strong>ribavirin</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=20</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>All</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=41</strong></p></td></tr><tr><td style="vertical-align:top"><p>End of treatment</p><p>&nbsp;</p><p>HCV RNA</p><p>undetectable</p></td><td><p>70 (100%)</p></td><td><p>56 (100%)</p></td><td><p>126 (100%)</p></td><td><p>19 (91%)</p></td><td><p>19 (95%)</p></td><td><p>38 (93%)</p></td></tr><tr><td style="vertical-align:top"><p>SVR12 (overall)*</p></td><td><p>70 (100%)</p></td><td><p>55 (98%)*</p></td><td><p>125 (99%)*</p></td><td><p>21 (100%)</p></td><td><p>20 (100%)</p></td><td><p>41 (100%)</p></td></tr><tr><td style="vertical-align:top"><p>12 weeks</p><p>treatment</p><p>duration</p></td><td><p>41/41 (100%)</p></td><td><p>40/41 (98%)</p></td><td><p>81/82 (99%)</p></td><td><p><strong>-</strong></p></td><td><p><strong>-</strong></p></td><td><p><strong>-</strong></p></td></tr><tr><td style="vertical-align:top"><p>24 weeks</p><p>treatment</p><p>duration</p></td><td><p>29/29 (100%)</p></td><td><p>15/15 (100%)</p></td><td><p>44/44 (100%)</p></td><td><p>21 (100%)</p></td><td><p>20 (100%)</p></td><td><p>41 (100%)</p></td></tr><tr><td style="vertical-align:top"><p>&ge; F3 liver</p><p>fibrosis</p></td><td><p><strong>-</strong></p></td><td><p><strong>-</strong></p></td><td><p>41/41 (100%)</p></td><td><p><strong>-</strong></p></td><td><p><strong>-</strong></p></td><td><p>20/20 (100%)</p></td></tr></tbody></table><p>&nbsp;</p><p>* Patients who had missing data at follow-upWeek 12 were considered responders if their next available HCV RNAvalue was &lt;LLOQ. One treatment-na&iuml;vepatient was missing both post-treatment Weeks 12 and 24 data.</p><p>&nbsp;</p><p><strong>Table 7: Treatment outcomes, daclatasvir in combination with sofosbuvir for 24 weeks, treatment-na&iuml;vepatientswith HCV genotype 2 or 3 in Study AI444040</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Genotype 2</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Genotype 3</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>daclatasvir +</strong></p><p><strong>sofosbuvir</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=17</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>daclatasvir +</strong></p><p><strong>sofosbuvir +</strong></p><p><strong>ribavirin</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=9</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>All Genotype2</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=26</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>daclatasvir +</strong></p><p><strong>sofosbuvir</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=13</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>daclatasvir +</strong></p><p><strong>sofosbuvir +</strong></p><p><strong>ribavirin</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=5</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>All Genotype 3</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=18</strong></p></td></tr><tr><td style="vertical-align:top"><p>End of treatment</p><p>&nbsp;</p><p>HCV RNA</p><p>undetectable</p></td><td><p>17 (100%)</p></td><td><p>9 (100%)</p></td><td><p>26 (100%)</p></td><td><p>11 (85%)</p></td><td><p>5 (100%)</p></td><td><p>16 (89%)</p></td></tr><tr><td style="vertical-align:top"><p>SVR12*</p></td><td><p>17 (100%)</p></td><td><p>8 (89%)*</p></td><td><p>25 (96%)*</p></td><td><p>11 (85%)</p></td><td><p>5 (100%)</p></td><td><p>16 (89%)</p></td></tr><tr><td style="vertical-align:top"><p>&ge; F3 liver</p><p>fibrosis</p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p>8/8 (100%)</p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p>5/5 (100%)</p></td></tr><tr><td colspan="7"><p><strong>Virologic failure</strong></p></td></tr><tr><td style="vertical-align:top"><p>Virologic</p><p>breakthrough**</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>1 (8%)</p></td><td><p>0</p></td><td><p>1 (6%)</p></td></tr><tr><td style="vertical-align:top"><p>Relapse**</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>1/11 (9%)</p></td><td><p>0</p></td><td><p>1/16 (6%)</p></td></tr></tbody></table><p>&nbsp;</p><p>* Patients who had missing data at follow-up Week 12 were considered responders if their next available HCV RNAvalue was &lt;LLOQ. One patient with HCV genotype 2 infection was missing both post-treatmentWeek 12 and 24 data.</p><p>&nbsp;</p><p>** The patient with virologic breakthrough met the original protocol definition of confirmed HCV RNA &lt;LLOQ, detectableat treatment Week 8. Relapse was defined as HCV RNA &ge;LLOQ during follow-upafter HCV RNA &lt;LLOQ at end oftreatment. Relapse includes observations through follow-upWeek 24.</p><p>&nbsp;</p><p><strong><em>Advanced cirrhosis and post-livertransplant (ALLY1)</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>In study ALLY1,the regimen of daclatasvir, sofosbuvir, and ribavirin administered for 12 weeks was evaluated in 113adults with chronic hepatitis C and Child-PughA, B or C cirrhosis (n=60) or HCV recurrence after liver transplantation(n=53). Patients with HCV genotype 1, 2, 3, 4, 5 or 6 infection were eligible to enroll. Patients received daclatasvir 60mg once daily, sofosbuvir 400 mg once daily, and ribavirin (600 mg starting dose) for 12 weeks and were monitored for24 weeks post treatment. Patients demographics and main disease characteristics are summarized in Table 8.</p><p>&nbsp;</p><p><strong>Table 8: Demographics and main disease characteristics in Study ALLY1</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Cirrhotic cohort</strong></p><p><strong>&nbsp;</strong></p><p><strong>N = 60</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Post-Liver Transplant</strong></p><p><strong>&nbsp;</strong></p><p><strong>N = 53</strong></p></td></tr><tr><td style="vertical-align:top"><p>Age (years): median (range)</p><p>&nbsp;</p><p>Race: White</p><p>Black/African American</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other</p></td><td style="vertical-align:top"><p>58 (1975)</p><p>&nbsp;</p><p>57 (95%)</p><p>3 (5%)</p><p>0</p></td><td style="vertical-align:top"><p>59 (2282)</p><p>&nbsp;</p><p>51 (96%)</p><p>1 (2%)</p><p>1 (2%)</p></td></tr><tr><td style="vertical-align:top"><p>HCV genotype:</p><p>1a</p><p>1b</p><p>2</p><p>3</p><p>4</p><p>6</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>34 (57%)</p><p>11 (18%)</p><p>5 (8%)</p><p>6 (10%)</p><p>4 (7%)</p><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>31 (58%)</p><p>10 (19%)</p><p>0</p><p>11 (21%)</p><p>0</p><p>1 (2%)</p></td></tr><tr><td style="vertical-align:top"><p>Fibrosis stage</p><p>F0</p><p>F1</p><p>F2</p><p>F3</p><p>F4</p><p>Not reported</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0</p><p>1 (2%)</p><p>3 (5%)</p><p>8 (13%)</p><p>48 (80%)</p><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>6 (11%)</p><p>10 (19%)</p><p>7 (13%)</p><p>13 (25%)</p><p>16 (30%)</p><p>1 (2%)</p></td></tr><tr><td style="vertical-align:top"><p>CP classes</p><p>CP A</p><p>CP B</p><p>CP C</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>12 (20%)</p><p>32 (53%)</p><p>16 (27%)</p></td><td style="vertical-align:top"><p>ND</p></td></tr><tr><td style="vertical-align:top"><p>MELD score</p><p>mean</p><p>median</p><p>Q1, Q3</p><p>&nbsp;&nbsp; Min, Max</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>13.3</p><p>13.0</p><p>10, 16</p><p>8, 27</p></td><td style="vertical-align:top"><p>ND</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>ND: Not determined</p><p>&nbsp;</p><p>SVR12 was achieved by 83% (50/60) of patients in the cirrhosis cohort, with a marked difference between patients withChild-PughA or B (92-94%)as compared to those with Child-PughC and 94% of patients in the post-livertransplantcohort (Table 9). SVR rates were comparable regardless of age, race, gender, IL28B allele status, or baseline HCV RNA level. In the cirrhosis cohort, 4 patients with hepatocellular carcinoma underwent liver transplantation after 1&ndash;71 days oftreatment; 3 of the 4 patients received 12 weeks of post-livertransplant treatment extension and 1 patient, treated for23 days before transplantation, did not receive treatment extension. All 4 patients achieved SVR12.</p><p>&nbsp;</p><p><strong>Table 9: Treatment outcomes, daclatasvir in combination with sofosbuvir and ribavirin for 12 weeks, patientswith cirrhosis or HCV recurrence after liver transplantation, Study ALLY1</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Cirrhotic cohort</strong></p><p><strong>N=60</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Post-Liver Transplant</strong></p><p><strong>N=53</strong></p></td></tr><tr><td style="vertical-align:top"><p>End of treatment</p><p>&nbsp;</p><p>HCV RNA</p><p>undetectable</p></td><td colspan="2"><p>58/60 (97%)</p></td><td colspan="2"><p>53/53 (100%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>SVR12</strong></p></td><td style="vertical-align:top"><p><strong>Relapse</strong></p></td><td style="vertical-align:top"><p><strong>SVR12</strong></p></td><td style="vertical-align:top"><p><strong>Relapse</strong></p></td></tr><tr><td style="vertical-align:top"><p>All patients</p></td><td style="vertical-align:top"><p>50/60 (83%)</p></td><td style="vertical-align:top"><p>9/58* (16%)</p></td><td style="vertical-align:top"><p>50/53 (94%)</p></td><td style="vertical-align:top"><p>3/53 (6%)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>ND</p></td></tr><tr><td style="vertical-align:top"><p>CP A</p></td><td style="vertical-align:top"><p>11/12 (92%)</p></td><td style="vertical-align:top"><p>1/12 (8%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>CP B</p></td><td style="vertical-align:top"><p>30/32 (94%)</p></td><td style="vertical-align:top"><p>2/32 (6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>CP C</p></td><td style="vertical-align:top"><p>9/16 (56%)</p></td><td style="vertical-align:top"><p>6/14 (43%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 1</p></td><td style="vertical-align:top"><p>37/45 (82%)</p></td><td style="vertical-align:top"><p>7/45 (16%)</p></td><td style="vertical-align:top"><p>39/41 (95%)</p></td><td style="vertical-align:top"><p>2/41 (5%)</p></td></tr><tr><td style="vertical-align:top"><p>1a</p></td><td style="vertical-align:top"><p>26/34 (77%)</p></td><td style="vertical-align:top"><p>7/33 (21%)</p></td><td style="vertical-align:top"><p>30/31 (97%)</p></td><td style="vertical-align:top"><p>1/31 (3%)</p></td></tr><tr><td style="vertical-align:top"><p>1b</p></td><td style="vertical-align:top"><p>11/11 (100%)</p></td><td style="vertical-align:top"><p>0%</p></td><td style="vertical-align:top"><p>9/10 (90%)</p></td><td style="vertical-align:top"><p>1/10 (10%)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 2</p></td><td style="vertical-align:top"><p>4/5 (80%)</p></td><td style="vertical-align:top"><p>1/5 (20%)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 3</p></td><td style="vertical-align:top"><p>5/6 (83%)</p></td><td style="vertical-align:top"><p>1/6 (17%)</p></td><td style="vertical-align:top"><p>10/11 (91%)</p></td><td style="vertical-align:top"><p>1/11 (9%)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 4</p></td><td style="vertical-align:top"><p>4/4 (100%)</p></td><td style="vertical-align:top"><p>0%</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 6</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>1/1 (100%)</p></td><td style="vertical-align:top"><p>0%</p></td></tr></tbody></table><p>&nbsp;</p><p>ND: Not determined</p><p>&nbsp;</p><p>* 2 patients had detectable HCV RNA at end of treatment; 1 of these patients achieved SVR.</p><p><em>&nbsp;</em></p><p><strong><em>HCV/HIV co-infection(ALLY2)</em></strong></p><p><em>&nbsp;</em></p><p>In study ALLY2,the combination of daclatasvir and sofosbuvir administered for 12 weeks was evaluated in 153 adultswith chronic hepatitis C and HIV coinfection;101 patients were HCV treatment-na&iuml;veand 52 patients had failed priorHCV therapy. Patients with HCV genotype 1, 2, 3, 4, 5, or 6 infection were eligible to enroll, including patients withcompensated cirrhosis (Child-PughA). The dose of daclatasvir was adjusted for concomitant antiretroviral use. Patientdemographics and baseline disease characteristics are summarized in Table 10.</p><p>&nbsp;</p><p><strong>Table 10: Demographics and baseline characteristics in Study ALLY2</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Patient disposition</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>daclatasvir + sofosbuvir</strong></p><p><strong>&nbsp;</strong></p><p><strong>12 weeks</strong></p><p><strong>&nbsp;</strong></p><p><strong>N = 153</strong></p></td></tr><tr><td style="vertical-align:top"><p>Age (years): median (range)</p></td><td style="vertical-align:top"><p>53 (24-71)</p></td></tr><tr><td style="vertical-align:top"><p>Race:</p><p>White</p><p>Black/African American</p><p>Other</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>97 (63%)</p><p>50 (33%)</p><p>6 (4%)</p></td></tr><tr><td style="vertical-align:top"><p>HCV genotype:</p><p>1a</p><p>1b</p><p>2</p><p>3</p><p>4</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>104 (68%)</p><p>23 (15%)</p><p>13 (8%)</p><p>10 (7%)</p><p>3 (2%)</p></td></tr><tr><td style="vertical-align:top"><p>Compensated cirrhosis</p></td><td style="vertical-align:top"><p>24 (16%)</p></td></tr><tr><td style="vertical-align:top"><p>Concomitant HIV therapy:</p><p>PI-based</p><p>NNRTI-based</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; None</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>70 (46%)</p><p>40 (26%)</p><p>41 (27%)</p><p>2 (1%)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Overall, SVR12 was achieved by 97% (149/153) of patients administered daclatasvir and sofosbuvir for 12 weeks inALLY2.SVR rates were &gt;94% across combinationantiretroviral therapy (cART) regimens, including boosted-PI,NNRTI,and integrase inhibitor (INSTI)-basedtherapies.</p><p>&nbsp;</p><p>SVR rates were comparable regardless of HIV regimen, age, race, gender, IL28B allele status, or baseline HCV RNAlevel. Outcomes by prior treatment experience are presented in Table 11.</p><p>&nbsp;</p><p>A third treatment group in study ALLY2included 50 HCV treatment-na&iuml;veHIV co-infectedpatients who receiveddaclatasvir and sofosbuvir for 8 weeks. Demographic and baseline characteristics of these 50 patients were generallycomparable to those for patients who received 12 weeks of study treatment. The SVR rate for patients treated for 8weeks was lower with this treatment duration as summarized in Table 11.</p><p>&nbsp;</p><p><strong>Table 11: Treatment outcomes, daclatasvir in combination with sofosbuvir in patients with HCV/HIV coinfectionin Study ALLY2</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>8 weeks therapy</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>12 weeks therapy</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>HCV Treatment-na&iuml;ve</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=50</strong></p></td><td style="vertical-align:top"><p><strong>HCV Treatment-na&iuml;ve</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=101</strong></p></td><td style="vertical-align:top"><p><strong>HCV Treatment-experienced*</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=52</strong></p></td></tr><tr><td style="vertical-align:top"><p>End of treatment</p><p>&nbsp;</p><p>HCV RNA undetectable</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>50/50 (100%)</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>100/101 (99%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>52/52 (100%)</p></td></tr><tr><td style="vertical-align:top"><p>SVR12</p></td><td style="vertical-align:top"><p>38/50 (76%)</p></td><td style="vertical-align:top"><p>98/101 (97%)</p></td><td style="vertical-align:top"><p>51/52 (98%)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis**</p></td><td style="vertical-align:top"><p>34/44 (77%)</p></td><td style="vertical-align:top"><p>88/90 (98%)</p></td><td style="vertical-align:top"><p>34/34 (100%)</p></td></tr><tr><td style="vertical-align:top"><p>With cirrhosis**</p></td><td style="vertical-align:top"><p>3/5 (60%)</p></td><td style="vertical-align:top"><p>8/9 (89%)</p></td><td style="vertical-align:top"><p>14/15 (93%)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 1</p></td><td style="vertical-align:top"><p>31/41 (76%)</p></td><td style="vertical-align:top"><p>80/83 (96%)</p></td><td style="vertical-align:top"><p>43/44 (98%)</p></td></tr><tr><td style="vertical-align:top"><p>1a</p></td><td style="vertical-align:top"><p>28/35 (80%)</p></td><td style="vertical-align:top"><p>68/71 (96%)</p></td><td style="vertical-align:top"><p>32/33 (97%)</p></td></tr><tr><td style="vertical-align:top"><p>1b</p></td><td style="vertical-align:top"><p>3/6 (50%)</p></td><td style="vertical-align:top"><p>12/12 (100%)</p></td><td style="vertical-align:top"><p>11/11 (100%)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 2</p></td><td style="vertical-align:top"><p>5/6 (83%)</p></td><td style="vertical-align:top"><p>11/11 (100%)</p></td><td style="vertical-align:top"><p>2/2 (100%)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 3</p></td><td style="vertical-align:top"><p>2/3 (67%)</p></td><td style="vertical-align:top"><p>6/6 (100%)</p></td><td style="vertical-align:top"><p>4/4 (100%)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 4</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1/1 (100%)</p></td><td style="vertical-align:top"><p>2/2 (100%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Virologic failure</strong></p></td></tr><tr><td style="vertical-align:top"><p>Detectable HCV RNA at end of treatment</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1/101 (1%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Relapse</p></td><td style="vertical-align:top"><p>10/50 (20%)</p></td><td style="vertical-align:top"><p>1/100 (1%)</p></td><td style="vertical-align:top"><p>1/52 (2%)</p></td></tr><tr><td style="vertical-align:top"><p>Missing post-treatment data</p></td><td style="vertical-align:top"><p>2/50 (4%)</p></td><td style="vertical-align:top"><p>1/101 (1%)</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>* Mainly interferon-based therapy +/-NS3/4 PI.</p><p>&nbsp;</p><p>** Cirrhosis was determined by liver biopsy, FibroScan &gt;14.6 kPa, or FibroTest score &ge;0.75 and aspartateaminotransferase (AST): platelet ratio index (APRI) &gt;2. For 5 patients, cirrhosis status was indeterminate.</p><p>&nbsp;</p><p><strong><em>HCV Genotype 3 (ALLY3)</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>In study ALLY3,the combination of daclatasvir and sofosbuvir administered for 12 weeks was evaluated in 152 adultsinfected with HCV genotype 3; 101 patients were treatment-na&iuml;veand 51 patients had failed prior antiviral therapy.</p><p>Median age was 55 years (range: 24 to 73) ; 90% of patients were white; 4% were black/African-American;5% wereAsian; 16% were Hispanic or Latino. The median viral load was 6.42 log10 IU/ml, and 21% of patients had compensatedcirrhosis. Most patients (61%) had IL-28Brs12979860 non-CCgenotypes.</p><p>&nbsp;</p><p>SVR12 was achieved in 90% of treatment-na&iuml;vepatients and 86% of Treatment-experiencedpatients. Response wasrapid (viral load at Week 4 showed that more than 95% of patients responded to therapy) and was not influenced byIL28B genotype. SVR12 rates were lower among patients with cirrhosis (see Table 12).</p><p>&nbsp;</p><p><strong>Table 12: Treatment outcomes, daclatasvir in combination with sofosbuvir for 12 weeks, patients with HCVgenotype 3 in Study ALLY3</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Treatment-na&iuml;ve</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=101</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Treatment-experienced*</strong></p><p><strong>N=51</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Total</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=152</strong></p></td></tr><tr><td style="vertical-align:top"><p>End of treatment</p><p>&nbsp;</p><p>HCV RNA undetectable</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>100 (99%)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>51 (100%)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>151 (99%)</p></td></tr><tr><td style="vertical-align:top"><p>SVR12</p></td><td style="vertical-align:top"><p>91 (90%)</p></td><td style="vertical-align:top"><p>44 (86%)</p></td><td style="vertical-align:top"><p>135 (89%)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis**</p></td><td style="vertical-align:top"><p>73/75 (97%)</p></td><td style="vertical-align:top"><p>32/34 (94%)</p></td><td style="vertical-align:top"><p>105/109 (96%)</p></td></tr><tr><td style="vertical-align:top"><p>With cirrhosis**</p></td><td style="vertical-align:top"><p>11/19 (58%)</p></td><td style="vertical-align:top"><p>9/13 (69%)</p></td><td style="vertical-align:top"><p>20/32 (63%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Virologic failure</strong></p></td></tr><tr><td style="vertical-align:top"><p>Virologic breakthrough</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Detectable HCV RNA at end of treatment</p></td><td style="vertical-align:top"><p>1 (1%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1 (0.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Relapse</p></td><td style="vertical-align:top"><p>9/100 (9%)</p></td><td style="vertical-align:top"><p>7/51 (14%)</p></td><td style="vertical-align:top"><p>16/151 (11%)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>* Mainly interferon-basedtherapy, but 7 patients received sofosbuvir + ribavirin and 2 patients received a cyclophilininhibitor.</p><p>&nbsp;</p><p>** Cirrhosis was determined by liver biopsy (METAVIR F4) for 14 patients, FibroScan &gt;14.6 kPa for 11 patients orFibroTest score &ge;0.75 and aspartate aminotransferase (AST): platelet ratio index (APRI) &gt;2 for 7 patients. For 11patients, cirrhosis status was missing or inconclusive (FibroTest score &gt;0.48 to &lt;0.75 or APRI &gt;1 to &le;2).</p><p>&nbsp;</p><p><u>Compassionate Use</u></p><p>Patients with HCV infection (across genotypes) at high risk of decompensation or death within 12 months if leftuntreated were treated under compassionate use programmes. Patients with genotype 3 infection were treated withdaclatasvir + sofosbuvir +/-ribavirin</p><p>for 12 or 24 weeks, where the longer treatment duration was associated with alower risk for relapse (around 5%) in a preliminary analysis. The relevance of including ribavirin as part of the 24-weekregimen is unclear. In one cohort the majority of patients were treated with daclatasvir + sofosbuvir + ribavirin for 12weeks. The relapse rate was around 15%, and similar for patients with Child-PughA, B and C. The programmes do notallow for a direct comparison of efficacy between the 12and24-weekregimens.</p><p><em>&nbsp;</em></p><p><em>Daclatasvir in combination with peginterferon alfa and ribavirin</em></p><p><em>&nbsp;</em></p><p>AI444042 and AI444010 were randomised, double-blind studies that evaluated the efficacy and safety of daclatasvir incombination with peginterferon alfa and ribavirin (pegIFN/RBV) in the treatment of chronic HCV infection in treatment-na&iuml;veadults with compensated liver disease (including cirrhosis). AI444042 enrolled patients with HCV genotype 4infection and AI444010 enrolled patients with either genotype 1 or 4. AI444043 was an open-label,single-armstudy ofdaclatasvir with pegIFN/RBV in treatment-na&iuml;veadults with chronic HCV genotype 1 infection who were co-infected</p><p>WithHIV.</p><p>&nbsp;</p><p>AI444042: Patients received daclatasvir 60 mg once daily (n=82) or placebo (n=42) plus pegIFN/RBV for 24 weeks.Patients in the daclatasvir treatment group who did not have HCV RNA undetectable at both Weeks 4 and 12 and allplacebo-treatedpatients continued pegIFN/RBV for another 24 weeks. Treated patients had a median age of 49 years(range: 20 to 71) ; 77% of patients were white; 19% were black/African-American;</p><p>4% were Hispanic or Latino. Tenpercent of patients had compensated cirrhosis, and 75% of patients had IL28Brs12979860 non-CCgenotypes.</p><p>Treatment outcomes in study AI444042 are presented in Table 13. Response was rapid (at Week 4 91% of daclatasvir-treatedpatients had HCV RNA &lt;LLOQ). SVR12 rates were higher for patients with the IL28BCC genotype than forthose with non-CC</p><p>genotypes and for patients with baseline HCV RNA less than 800,000 IU/ml but consistently higherin the daclatasvir-treated patients than for placebo-treated patients in all subgroups.</p><p>&nbsp;</p><p>AI444010: Patients received daclatasvir 60 mg once daily (n=158) or placebo (n=78) plus pegIFN/RBV through Week12. Patients assigned to daclatasvir 60 mg once-daily treatment group who had HCV RNA &lt;LLOQ at Week 4 and undetectable at Week 10 were then randomised to receive another 12 weeks of daclatasvir 60 mg + pegIFN/RBV orplacebo + pegIFN/RBV for a total treatment duration of 24 weeks. Patients originally assigned to placebo and those inthe daclatasvir group who did not achieve HCV RNA &lt;LLOQ at Week 4 and undetectable at Week 10 continuedpegIFN/RBV to complete 48 weeks of treatment. Treated patients had a median age of 50 years (range: 18 to 67) ; 79%</p><p>of patients were white; 13% were black/African-American;1% were Asian; 9% were Hispanic or Latino. Seven percentof patients had compensated cirrhosis; 92% had HCV genotype 1 (72% 1a and 20% 1b) and 8% had HCV genotype 4;65% of patients had IL28Brs12979860 non-CC genotypes.</p><p>&nbsp;</p><p>Treatment outcomes in study AI444010 for patients with HCV genotype 4 are presented in Table 13. For HCV genotype1, SVR12 rates were 64% (54% for 1a; 84% for 1b) for patients treated with daclatasvir + pegIFN/RBV and 36% forpatients treated with placebo + pegIFN/RBV. For daclatasvir-treated patients with HCV RNA results at both follow-upWeeks 12 and 24, concordance of SVR12 and SVR24 was 97% for HCV genotype 1 and 100% for HCV genotype 4.</p><p>&nbsp;</p><p><strong>Table 13: Treatment outcomes, daclatasvir in combination with peginterferon alfa and ribavirin (pegIFN/RBV),treatment-na&iuml;vepatients with HCV genotype 4</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study AI444042</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study AI444010</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>daclatasvir +</strong></p><p><strong>pegIFN/RBV</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=82</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>pegIFN/RBV</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=42</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>daclatasvir +</strong></p><p><strong>pegIFN/RBV</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=12</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>pegIFN/RBV</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=6</strong></p></td></tr><tr><td style="vertical-align:top"><p>End of treatment</p><p>&nbsp;</p><p>HCV RNA</p><p>undetectable</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>74 (90%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>27 (64%)</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>12 (100%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>4 (67%)</p></td></tr><tr><td style="vertical-align:top"><p>SVR12*</p></td><td style="vertical-align:top"><p>67 (82%)</p></td><td style="vertical-align:top"><p>18 (43%)</p></td><td style="vertical-align:top"><p>12 (100%)</p></td><td style="vertical-align:top"><p>3 (50%)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td style="vertical-align:top"><p>56/69 (81%)**</p></td><td style="vertical-align:top"><p>17/38 (45%)</p></td><td style="vertical-align:top"><p>12/12 (100%)</p></td><td style="vertical-align:top"><p>3/6 (50%)</p></td></tr><tr><td style="vertical-align:top"><p>With cirrhosis</p></td><td style="vertical-align:top"><p>7/9 (78%)**</p></td><td style="vertical-align:top"><p>1/4 (25%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Virologic failure</strong></p></td></tr><tr><td style="vertical-align:top"><p>On-treatment</p><p>virologic</p><p>failure</p></td><td style="vertical-align:top"><p>8 (10%)</p></td><td style="vertical-align:top"><p>15 (36%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Relapse</p></td><td style="vertical-align:top"><p>2/74 (3%)</p></td><td style="vertical-align:top"><p>8/27 (30%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1/4 (25%)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>* Patients who had missing data at follow-upWeek 12 were considered responders if their next available HCV RNAvalue was &lt;LLOQ.</p><p>&nbsp;</p><p>** Cirrhosis status was not reported for four patients in the daclatasvir + pegIFN/RBV group.</p><p>&nbsp;</p><p>AI444043: 301 treatment-na&iuml;vepatients with HCV genotype 1 infection and HIV coinfection(10% with compensatedcirrhosis) were treated with daclatasvir in combination with pegIFN/RBV. The dose of daclatasvir was 60 mg once daily,with dose adjustments for concomitant antiretroviral use (see section 4.5). Patients achievingvirologic response [HCVRNA undetectable at weeks 4 and 12] completed therapy after 24 weeks while those who did not achieve virologicresponse received an additional 24 weeks of treatment with pegIFN/RBV, to complete a total of 48 weeks of studytherapy. SVR12 was achieved by 74% of patients in this study (genotype 1a: 70%, genotype 1b:79%).</p><p>&nbsp;</p><p><u>Long term efficacy data</u></p><p>Limited data are available from an ongoing follow-upstudy to assess durability of response up to 3 years after treatmentwith daclatasvir. Among patients who achieved SVR12 with daclatasvir and sofosbuvir (&plusmn; ribavirin) with a medianduration of post-SVR12 follow-upof 15 months, no relapses have occurred. Among patients who achieved SVR12 withdaclatasvir + pegIFN/RBV with a median duration of post-SVR12</p><p>follow-upof 22 months, 1% of patients relapsed.</p><p>&nbsp;</p><p><u>Resistance in clinical studies</u></p><p><em>Frequency of baseline NS5A resistance-associatedvariants (RAVs)</em></p><p><em>&nbsp;</em></p><p>Baseline NS5A RAVs were frequently observed in clinical studies of daclatasvir. In 9 phase 2/3 studies with daclatasvirin combination with peginterferon alfa + ribavirin or in combination with sofosbuvir +/-ribavirin,the following frequenciesof such RAVs were seen at baseline: 7% in genotype 1a infection (M28T, Q30, L31, and/or Y93) ; 11% in genotype 1binfection (L31 and/or Y93H), 51% in genotype 2 infection (L31M), 8% in genotype 3 infection (Y93H) and 64% ingenotype 4 infection (L28 and/or L30).</p><p><em>&nbsp;</em></p><p><strong><em>Daclatasvir in combination with sofosbuvir</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>Impact of baseline NS5A RAVs on cure rates</em></p><p><em>&nbsp;</em></p><p>The baseline NS5A RAVs described above had no major impact on cure rates in patients treated with sofosbuvir +daclatasvir +/-ribavirin,with the exception of the Y93H RAV in genotype 3 infection (seen in 16/192 [8%] of patients).The SVR12 rate in genotype3</p><p>infected patients with this RAV is reduced (in practice as relapse after end of treatment</p><p>response), especially in patients with cirrhosis. The overall cure rate for genotype-3infected patients who were treated for 12 weeks with sofosbuvir + daclatasvir (without ribavirin) in the presence and absence of the Y93H RAV was 7/13(54%) and 134/145 (92%), respectively. There was no Y93H RAV present at baseline for genotype-3 infected patients treated for 12-weekswith sofosbuvir + daclatasvir + ribavirin, and thus SVR outcomes cannot be assessed.</p><p><em>&nbsp;</em></p><p><em>Emerging resistance</em></p><p>&nbsp;</p><p>In a pooled analysis of 629 patients who received daclatasvir and sofosbuvir with or without ribavirin in Phase 2 and 3studies for 12 or 24 weeks,34 patients qualified for resistance analysis due to virologic failure or early studydiscontinuation and having HCV RNA greater than 1,000 IU/ml. Observed emergent NS5A resistance-associated</p><p>variants are reported in Table 14.</p><p>&nbsp;</p><p><strong>Table 14: Summary of noted newly emergent HCV NS5A substitutions on treatment or during follow-upintreated non-SVR12subjects infected with HCV genotypes 1 through 3</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Category/ Substitution, n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Genotype 1a</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=301</strong></p></td><td style="vertical-align:top"><p><strong>Genotype 1b</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=79</strong></p></td><td style="vertical-align:top"><p><strong>Genotype 2</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=44</strong></p></td><td style="vertical-align:top"><p><strong>Genotype 3</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=197</strong></p></td></tr><tr><td style="vertical-align:top"><p>Non-responders</p><p>(non-SVR12)</p></td><td style="vertical-align:top"><p>14*</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2*</p></td><td style="vertical-align:top"><p>21**</p></td></tr><tr><td style="vertical-align:top"><p>with baseline and post-baseline</p><p>sequence</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>with emergent NS5A RAVs***</p></td><td style="vertical-align:top"><p>10 (83%)</p></td><td style="vertical-align:top"><p>1 (100%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>16 (80%)</p></td></tr><tr><td style="vertical-align:top"><p>M28: T</p></td><td style="vertical-align:top"><p>2 (17%)</p></td><td style="vertical-align:top"><p><strong>--</strong></p></td><td style="vertical-align:top"><p><strong>--</strong></p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Q30: H, K, R</p></td><td style="vertical-align:top"><p>9 (75%)</p></td><td style="vertical-align:top"><p><strong>--</strong></p></td><td style="vertical-align:top"><p><strong>--</strong></p></td><td style="vertical-align:top"><p><strong>--</strong></p></td></tr><tr><td style="vertical-align:top"><p>L31: I, M, V</p></td><td style="vertical-align:top"><p>2 (17%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1 (5%)</p></td></tr><tr><td style="vertical-align:top"><p>P32-deletion</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1 (100%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>H58: D, P</p></td><td style="vertical-align:top"><p>2 (17%)</p></td><td style="vertical-align:top"><p><strong>--</strong></p></td><td style="vertical-align:top"><p><strong>--</strong></p></td><td style="vertical-align:top"><p><strong>--</strong></p></td></tr><tr><td style="vertical-align:top"><p>S62: L</p></td><td style="vertical-align:top"><p><strong>--</strong></p></td><td style="vertical-align:top"><p><strong>--</strong></p></td><td style="vertical-align:top"><p><strong>--</strong></p></td><td style="vertical-align:top"><p>2 (10%)</p></td></tr><tr><td style="vertical-align:top"><p>Y93: C, H, N</p></td><td style="vertical-align:top"><p>2 (17%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>11 (55%)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>* Patient(s) lost to follow-up</p><p>&nbsp;</p><p>** One patient considered a protocol failure (non-SVR)achieved SVR</p><p>&nbsp;</p><p>*** NS5A RAVs monitored at amino acid positions are 28, 29, 30, 31, 32, 58, 62, 92, and 93</p><p>&nbsp;</p><p>The sofosbuvir resistance-associated substitution S282T emerged in only 1 non-SVR12</p><p>patient infected with genotype3.</p><p>&nbsp;</p><p>No data are available on the persistence of daclatasvir resistance-associated substitutions beyond 6 months post-treatmentin patients treated with daclatasvir and sofosbuvirwith/without ribavirin. Emergent daclatasvir resistance-associated substitutions have been shown to persist for 2 years post-treatmentand beyond for patients treated withother daclatasvir-based regimens.</p><p><em>&nbsp;</em></p><p><strong><em>Daclatasvir in combination with peginterferon alfa and ribavirin</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Baseline NS5A RAVs (at M28T, Q30, L31, and Y93 for genotype 1a; at L31 and Y93 for genotype 1b) increase the riskfor nonresponsein treatment-na&iuml;ve patients infected with genotype 1a and genotype 1b infection. The impact ofbaseline NS5A RAVs on curerates of genotype 4 infection is not apparent.</p><p>&nbsp;</p><p>In case of nonresponseto therapy with daclatasvir + peginterferon alfa + ribavirin, NS5A RAVs generally emerged atfailure (139/153 genotype 1a and 49/57 genotype 1b). The most frequently detected NS5A RAVs included Q30E orQ30R in combination withL31M. The majority of genotype 1a failures had emergent NS5A variants detected at Q30</p><p>(127/139 [91%]), and the majority of genotype 1b failures had emergent NS5A variants detected at L31 (37/49 [76%])and/or Y93H (34/49 [69%]). In limited numbers of genotype 4-infectedpatients with nonresponse,substitutions L28Mand L30H/S were detected at failure.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with daclatasvir in one ormore subsets of the paediatric population in the treatment of chronic hepatitis C (see section 4.2 for information onpaediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of daclatasvir were evaluated in healthy adult subjects and in patients with chronicHCV. Following multiple oral doses of daclatasvir 60 mg once daily in combination with peginterferon alfa and ribavirin intreatment-na&iuml;ve</p><p>patients with genotype 1 chronic HCV, the geometric mean (CV%) daclatasvir Cmax was 1534 (58)ng/ml, AUC024hwas 14122 (70) ng&bull;h/ml, and Cmin was 232 (83) ng/ml.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Daclatasvir administered as a tablet was readily absorbed following multiple oral doses with peak plasma concentrationsoccurring between 1 and 2 hours.</p><p>&nbsp;</p><p>Daclatasvir Cmax, AUC, and Cmin increased in a near dose-proportionalmanner. Steady state was achieved after 4 daysof once-dailyadministration. At the 60 mg dose, exposure to daclatasvir was similar between healthy subjects andHCV-infected</p><p>patients.</p><p><em>&nbsp;</em></p><p><em>In vitro </em>and <em>in vivo </em>studies showed that daclatasvir is a substrate of Pgp.The absolute bioavailability of the tabletformulation is 67%.</p><p><em>&nbsp;</em></p><p><em>Effect of food on oral absorption</em></p><p><em>&nbsp;</em></p><p>In healthy subjects, administration of daclatasvir 60 mg tablet after a high-fatmeal decreased daclatasvir Cmax andAUC by 28% and 23%, respectively, compared with administration under fasting conditions. Administration ofdaclatasvir 60 mg tablet after a light meal resulted in no reduction in daclatasvir exposure.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>At steady state, protein binding of daclatasvir in HCV-infectedpatients wasapproximately 99% and independent of dose at the dose range studied (1 mg to 100 mg). In patients who received daclatasvir 60 mg tablet orally followed by100 &mu;g [13C,15N]-daclatasvirintravenous dose, estimated volume of distribution at steady state was 47 l. <em>In vitro</em>studies indicate that daclatasvir is actively and passively transported intohepatocytes. The active transport is mediated by OCT1 and other unidentified uptake transporters, but not by organic anion transporter (OAT) 2, sodium-taurocholate</p><p>cotransporting polypeptide (NTCP), or OATPs.</p><p>&nbsp;</p><p>Daclatasvir is an inhibitor of Pgp,OATP 1B1 and BCRP. <em>In vitro </em>daclatasvir is an inhibitor of renal uptake transporters,OAT1 and 3, and OCT2, but is not expected to have a clinical effect on the pharmacokinetics of substrates of thesetransporters.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><em>In vitro </em>and <em>in vivo </em>studies demonstrate that daclatasvir is a substrate of CYP3A, with CYP3A4 being the major CYPisoform responsible for the metabolism. No metabolites circulated at levels more than 5% of the parent concentration.Daclatasvir <em>in vitro </em>did not inhibit (IC50 &gt;40 &mu;M) CYP enzymes 1A2, 2B6, 2C8, 2C9, 2C19, or 2D6.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Following single-doseoral administration of 14C&ndash;daclatasvir in healthy subjects, 88% of total radioactivity wasrecovered in feces (53% as unchanged drug) and 6.6% was excreted in the urine (primarily as unchanged drug). Thesedata indicate that the liver is the major clearance organ for daclatasvir in humans. <em>In vitro </em>studies indicate that</p><p>daclatasvir is actively and passively transported into hepatocytes. The active transport is mediated by OCT1 and otherunidentified uptake transporters. Following multiple-dose</p><p>administration of daclatasvir in HCV-infectedpatients, theterminal elimination half-life</p><p>of daclatasvir ranged from 12 to 15 hours. In patients who received daclatasvir 60 mg tabletorally followed by 100 &mu;g [13C,15N]-daclatasvirintravenous dose, the total clearance was 4.24 l/h.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Renal impairment</em></p><p>&nbsp;</p><p>The pharmacokinetics of daclatasvir following a single 60 mg oral dose were studied in non-HCVinfected subjects withrenal impairment. Daclatasvir unbound AUC was estimated to be 18%, 39% and 51% higher for subjects with creatinineclearance (CLcr) values of 60, 30 and 15 ml/min, respectively, relative to subjects with normal renal function. Subjectswith end-stagerenal disease requiring haemodialysis had a 27% increase in daclatasvir AUC and a 20% increase inunbound AUC compared to subjects with normal renal function (see section 4.2).</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>&nbsp;</p><p>The pharmacokinetics of daclatasvir following a single 30 mg oral dose were studied in non-HCVinfected subjects withmild (Child-PughA), moderate (Child-PughB), and severe (Child-PughC) hepatic impairment compared with unimpairedsubjects. The Cmax and AUC of total daclatasvir (free and protein-bounddrug) were lower in subjects with hepaticimpairment; however, hepatic impairment did not have a clinicallysignificant effect on the free drug concentrations of daclatasvir (see section 4.2).</p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p><em>&nbsp;</em></p><p>Population pharmacokinetic analysis of data from clinical studies indicated that age had no apparent effect on thepharmacokinetics of daclatasvir.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>The pharmacokinetics of daclatasvir in paediatric patients have not been evaluated.</p><p>&nbsp;</p><p><em>Gender</em></p><p><em>&nbsp;</em></p><p>Population pharmacokinetic analysis identified gender as a statistically significant covariate on daclatasvir apparent oralclearance (CL/F) with female subjects having slightly lower CL/F, but the magnitude of the effect on daclatasvirexposure is not clinically important.</p><p><em>&nbsp;</em></p><p><em>Race</em></p><p>&nbsp;</p><p>Population pharmacokinetic analysis of data from clinical studies identified race (categories &ldquo;other&rdquo; [patients who are notwhite, black or Asian] and &ldquo;black&rdquo;) as a statistically significant covariate on daclatasvir apparent oral clearance (CL/F)</p><p>and apparent volume of distribution (Vc/F) resulting in slightly higher exposures compared to white patients, but themagnitude of the effect on daclatasvir exposure is not clinically important.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Toxicology</u></p><p>In repeat-dose</p><p>toxicology studies in animals, hepatic effects (Kupffer-cellhypertrophy/ hyperplasia, mononuclear cellinfiltrates and bile duct hyperplasia) and adrenal gland effects (changes in cytoplasmic vacuolation and adrenal corticalhypertrophy/hyperplasia) were observed at exposures similar or slightly higher than the clinical AUC exposure. In dogs,bone marrow hypocellularity with correlating clinical pathology changes were observed at exposures 9-foldthe clinicalAUC exposure. None of these effects have been observed in humans.</p><p>&nbsp;</p><p><u>Carcinogenesis and mutagenesis</u></p><p>Daclatasvir was not carcinogenic in mice or in rats at exposures 8-foldor 4-fold, respectively, the clinical AUC exposure. No evidence of mutagenic or clastogenic activity was observed in <em>in vitro </em>mutagenesis (Ames) tests,mammalian mutation assays in Chinese hamster ovary cells, or in an <em>in vivo </em>oral micronucleus study in rats.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Daclatasvir had no effects on fertility in female rats at any dose tested. The highest AUC value in unaffected femaleswas 18-foldthe clinical AUC exposure. In male rats, effects on reproductive endpoints were limited to reducedprostate/seminal vesicle weights, and minimally increased dysmorphic sperm at 200 mg/kg/day; however, neitherfinding adversely affected fertility or the number of viable conceptuses sired. The AUC associated with this dose inmales is 19-foldthe clinical AUC exposure.</p><p>&nbsp;</p><p><u>Embryo-foetaldevelopment</u></p><p>Daclatasvir is embryotoxic and teratogenic in rats and rabbits at exposures at or above 4-fold(rat) and 16-fold(rabbit)the clinical AUC exposure. Developmental toxicity consisted of increased embryofoetal lethality, reduced foetal bodyweights and increased incidence of foetal malformations and variations. In rats, malformations mainly affected thebrain, skull, eyes, ears, nose, lip, palate or limbs and in rabbits, the ribs andcardiovascular area. Maternal toxicity including mortality, abortions, adverse clinical signs, decreases in body weight and food consumption was noted in bothspecies at exposures 25-fold(rat) and 72-fold(rabbit) the clinical AUC exposure.</p><p>&nbsp;</p><p>In a study of pre- andpostnatal development in rats, there was neither maternal nor developmental toxicity at doses upto 50 mg/kg/day, associated with AUC values 2-fold</p><p>the clinical AUC exposure. At the highest dose (100 mg/kg/day),maternal toxicity included mortality and dystocia; developmental toxicity included slight reductions in offspring viabilityin the peri- andneonatal periods; and reductions in birth weight that persisted into adulthood. The AUC value associatedwith this dose is 4-foldthe clinical AUC exposure.</p><p>&nbsp;</p><p><u>Excretion into milk</u></p><p>Daclatasvir was excreted into the milk of lactating rats with concentrations 1.7- to2-fold</p><p>maternal plasma levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Name of Ingredients</strong></p></td><td><p><strong>30mg</strong></p><p><strong>Unit Dose</strong></p><p><strong>(mg)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Daclatasvir Dihydrochloride</p></td><td><p>33.000</p></td></tr><tr><td style="vertical-align:bottom"><p>Avicel pH 112</p></td><td><p>29.000</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Lactose Anhydrous NF D.C.</strong></p></td><td><p><strong>85.250</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Croscarmellose Sodium Type A</p></td><td><p>4.650</p></td></tr><tr><td style="vertical-align:bottom"><p>Magnesium Stearate</p></td><td><p>1.550</p></td></tr><tr><td style="vertical-align:bottom"><p>Colloidal Silicon Dioxide</p></td><td><p>1.550</p></td></tr><tr><td style="vertical-align:bottom"><p>Opadry 03B110007 Green</p></td><td><p>4.650</p></td></tr><tr><td style="vertical-align:bottom"><p>Purified Water BP</p></td><td><p>Qs.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Total</strong></p></td><td><p>159.650</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
24 months/2 years.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p><p>&nbsp;</p><p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reel OPA/AL/PVC with Aluminum Foil.</p><p>&nbsp;</p><p>LEVERA 30 mg : Pack size of 28 film-coatedtablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordancewith local requirements.</p><p>&nbsp;</p><p>No Special Disposal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
SPIMACO
Al-Qassim Pharmaceutical Plant
Saudi Pharmaceutical Industries &
Medical Appliances Corporation.
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2017.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>